Document:

Manufacturing Agreement

 Exhibit 10.14 
 ***Text Omitted and Filed Separately 
 with the Securities and Exchange
Commission. 
 Confidential Treatment Requested 
 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 230.406 

MANUFACTURING AGREEMENT 
 DPT LAKEWOOD, LLC 
 AND 

INSYS THERAPEUTICS 
 Table of Contents 
  

											
	 I - DEFINITIONS
	  	 	4	  
					
		 	 1.1
	 		  	ACT	  	 	4	  
		 	 1.2
	 		  	FDA	  	 	4	  
		 	 1.3
	 		  	FORECASTED NEEDS	  	 	4	  
		 	 1.4
	 		  	LABEL, LABELED, OR LABELING	  	 	5	  
		 	 1.5
	 		  	MANUFACTURING FEE	  	 	5	  
		 	 1.6
	 		  	LAUNCH YEAR	  	 	5	  
		 	 1.7
	 		  	MATERIALS FEE	  	 	5	  
		 	 1.9
	 		  	PACKAGING	  	 	6	  
		 	 1.10
	 		  	PRODUCT(S)	  	 	6	  
		 	 1.11
	 		  	SPECIFICATIONS	  	 	6	  
		
	 II - PRODUCT MANUFACTURE AND SUPPLY
	  	 	6	  
					
		 	 2.1
	 		  	MANUFACTURE AND PURCHASE	  	 	6	  
		 	 2.2
	 		  	SUPPLY OF MATERIALS	  	 	7	  
		 		 	 (a)
	  	Materials Supplied by COMPANY	  	 	7	  
		 		 	 (b)
	  	Materials Supplied by DPT	  	 	8	  
		 		 	 (c)
	  	Packaging and Labeling	  	 	8	  
		 	 2.3
	 		  	MATERIALS TESTING	  	 	8	  
		 	 2.4
	 		  	MATERIAL SAFETY DATA SHEETS	  	 	9	  
		 	 2.5
	 		  	COMMENCEMENT OF MANUFACTURING FOR NEW PRODUCTS	  	 	9	  
		 	 2.6
	 		  	PURCHASE ORDERS	  	 	9	  
		 		 	 (a)
	  	 Purchase of Products
	  	 	9	  
		 		 	 (b)
	  	 Forecasted Needs
	  	 	9	  
		 		 	 (c)
	  	 Time of Issuance
	  	 	10	  
		 		 	 (d)
	  	 Contents of Purchase Orders
	  	 	10	  
		 	 2.7
	 		  	REJECTED PRODUCTS	  	 	11	  
		 		 	 (a)
	  	Rejection of Product by COMPANY	  	 	11	  
		 		 	 (b)
	  	Replacement of Rejected Product	  	 	11	  
		 		 	 (c)
	  	Responsibility for Costs	  	 	11	  
		 		 	 (d)
	  	Resolution of Conflict	  	 	12	  
		 	 2.8
	 		  	PRODUCT PRICE	  	 	13	  
		 		 	 (a)
	  	Manufacturing Fees	  	 	13	  
		 		 	 (b)
	  	Materials Fees	  	 	13	  
		 	 2.9
	 		  	PAYMENT	  	 	14	  
		 	 2.10
	 		  	LATE PAYMENT	  	 	14	  
		 	 2.11
	 		  	DISPOSAL COSTS	  	 	15	  

							
	 III - SHIPMENT AND RISK OF LOSS
	  	 	15	  
			
	 3.1
	 	SHIPMENT	  	 	15	  
	 3.2
	 	DELIVERY TERMS	  	 	15	  
	 3.3
	 	CLAIMS	  	 	15	  
		
	 IV - TERM AND TERMINATION
	  	 	16	  
			
	 4.1
	 	TERM	  	 	16	  
	 4.2
	 	TERMINATION	  	 	16	  
	 4.3
	 	PAYMENT ON TERMINATION	  	 	16	  
	 4.4
	 	SURVIVAL	  	 	16	  
		
	 V - CERTIFICATES OF ANALYSIS AND MANUFACTURING COMPLIANCE
	  	 	17	  
			
	 5.1
	 	CERTIFICATES OF ANALYSIS	  	 	17	  
	 5.2
	 	STABILITY TESTING	  	 	17	  
	 5.3
	 	VALIDATION WORK OR ADDITIONAL TESTING	  	 	17	  
	 5.4
	 	FDA INSPECTION	  	 	17	  
	 5.5
	 	REGULATORY FILINGS	  	 	18	  
		
	 VI - WARRANTIES
	  	 	18	  
			
	 6.1
	 	CONFORMITY WITH SPECIFICATIONS	  	 	18	  
	 6.2
	 	COMPLIANCE WITH THE ACT	  	 	18	  
	 6.3
	 	CONFORMITY WITH FDA REGULATIONS AND CGMP’S	  	 	18	  
	 6.4
	 	COMPLIANCE OF PACKAGING AND LABELING WITH LAWS AND
REGULATIONS	  	 	18	  
	 6.5
	 	ACCESS TO DPT’S FACILITIES	  	 	19	  
	 6.6
	 	DISCLAIMER	  	 	19	  
		
	 VII - FORCE MAJEURE
	  	 	19	  
		
	 VIII - CHANGES TO PROCESS OR PRODUCT
	  	 	20	  
			
	 8.1
	 	CHANGES BY COMPANY	  	 	20	  
	 8.2
	 	CHANGES BY DPT	  	 	20	  
	 8.3
	 	CHANGES BY REGULATORY AUTHORITIES	  	 	20	  
	 8.4
	 	OBSOLETE INVENTORY	  	 	21	  
		
	 IX - CONFIDENTIAL INFORMATION
	  	 	21	  
			
	 9.1
	 	CONFIDENTIAL INFORMATION	  	 	21	  
	 (a)
	 	Obligations of Confidentiality	  	 	21	  
	 (b)
	 	Exceptions	  	 	22	  
	 (c)
	 	DPT Business Model	  	 	22	  
	 9.2
	 	TRADEMARKS AND TRADE NAMES	  	 	22	  
	 9.3
	 	INVENTIONS AND PATENTS	  	 	23	  
		
	 Section 8 regarding Collaborative Efforts of the Research and Development Services Agreement between DPT and COMPANY dated
April 17, 2009, is hereby incorporated in its entirety by its reference and shall remain in effect for the term of this Agreement.
	  	 	23	  
		
	 X - RESEARCH & DEVELOPMENT SERVICES
	  	 	23	  
			
	 10.1
	 	R&D SERVICES	  	 	23	  
	 (a)
	 	Research Products	  	 	23	  
	 (b)
	 	Project Protocol	  	 	23	  
	 (c)
	 	Costs	  	 	24	  
	 (d)
	 	Obsolete Inventory	  	 	24	  
		
	 XI - INDEMNIFICATION
	  	 	25	  
			
	 11.1
	 	INDEMNIFICATION BY DPT	  	 	25	  
	 11.3
	 	INDEMNIFICATION BY COMPANY	  	 	25	  

  
 2 

							
	 11.6
	 	PATENT AND OTHER INTELLECTUAL PROPERTY RIGHTS	  	 	26	  
	 (a)
	 	Warranty by COMPANY	  	 	26	  
	 (b)
	 	Warranty by DPT	  	 	26	  
	 11.7
	 	CONDITIONS OF INDEMNIFICATION	  	 	26	  
		
	 XII - GENERAL PROVISIONS
	  	 	27	  
			
	 12.1
	 	NOTICES	  	 	27	  
	 12.2
	 	ENTIRE AGREEMENT; AMENDMENT	  	 	27	  
	 12.3
	 	WAIVER	  	 	28	  
	 12.4
	 	OBLIGATIONS TO THIRD PARTIES	  	 	28	  
	 12.5
	 	ASSIGNMENT	  	 	28	  
	 12.6
	 	GOVERNING LAW AND ARBITRATION	  	 	28	  
	 (a)
	 	Governing Law	  	 	28	  
	 (b)
	 	Arbitration	  	 	28	  
	 (c)
	 	Mediation	  	 	30	  
	 (d)
	 	Costs	  	 	32	  
	 12.7
	 	SEVERABILITY	  	 	32	  
	 12.8
	 	HEADINGS, INTERPRETATION	  	 	32	  
	 12.9     COUNTERPARTS
	  	 	32	  
	 12.10   INDEPENDENT CONTRACTOR
	  	 	32	  

  
 3 

 This Manufacturing Agreement (the “Agreement”) is made as of
this 24th day of May, 2011 (the “Effective Date”) by and between Insys Therapeutics, a corporation organized under the laws of the State of Delaware with its principal place of business at 10220 South 51st Street, Suite 2, Phoenix, AZ 85044 (hereinafter referred to as
“COMPANY”) and DPT Lakewood, LLC, a corporation organized under the laws of the State of Delaware with a place of business at 1200 Paco Way, Lakewood, New Jersey, 08701, including its affiliate DPT Laboratories, Ltd. (hereinafter
collectively referred to as “DPT”). 
 WITNESSETH: 

WHEREAS, COMPANY is engaged in the distribution and sale of certain pharmaceutical and/or cosmetic products; and 

WHEREAS, DPT owns and has a broad spectrum of technologies for the development, formulation, testing, control, manufacture,
filling and distribution of pharmaceutical, over-the-counter and cosmetic products; and 
 WHEREAS, COMPANY desires DPT
to manufacture and sell the Products hereinafter defined to COMPANY, and DPT desires to do so. 
 NOW, THEREFORE, in
consideration of the mutual covenants hereinafter expressed, the parties agree as follows: 
 I—DEFINITIONS

  

	1.1	Act 

 “Act”
means the Federal Food, Drug and Cosmetic Act, as amended, and regulations promulgated thereunder. 
  

	1.2	FDA 

 “FDA”
means the United States Food and Drug Administration, or any successor entity thereto. 
  

	1.3	Forecasted Needs 

“Forecasted Needs” means COMPANY’s estimate of Products to be ordered from DPT for each of the eighteen (18) months
following the month in which such estimate is provided. 

  
 4 

	1.4	Label, Labeled, or Labeling 

 “Label”, “Labeled”, or “Labeling” means all labels and other written, printed, or graphic matter upon: (i) Product or any container or wrapper utilized with Product or
(ii) any written material accompanying Product. 
  

	1.5	Manufacturing Fee 

“Manufacturing Fee” means the fee paid by COMPANY to DPT for services required to manufacture and package Products. The
Manufacturing Fee is quoted in single final Product unit increments (i.e. by the bottle or tube). The Manufacturing Fee shall include services for incoming inspection and testing of materials, compounding of bulk, packaging Product, testing Product
for release, making Product ready for shipment, and minimum product documentation (one copy of Certificate of Analysis.) The Manufacturing Fee does not include, without limitation, any research & development support, package engineering
studies, validation support, FDA audit support, extensive reporting requirements, or additional laboratory testing performed by an outside testing laboratory or testing beyond that required in the Specifications. These services are in addition to
the Manufacturing Fee and shall be billed by the hour at DPT’s then-prevailing R&D hourly rate in accordance with Section XI contained herein. In addition, the Manufacturing Fee does not include warehousing or distribution of Product, any
materials costs or costs associated with establishing or manufacturing new materials such as art charges, die costs, plate costs, and packaging equipment change parts. 
  

	1.6	Launch Year 

 “Launch
Year” means a period of a variable number of months commencing on the first day of the month following the initial invoicing of Product which has been commercially manufactured by DPT in accordance with the terms and conditions of this
Agreement and ending on December 31 of the year of the initial invoicing. 
  

	1.7	Materials Fee 

“Materials Fee” is quoted in single final Product unit increments and is defined as DPT’s Standard Cost (“Standard
Cost” is the average actual cost to DPT of materials plus incoming freight, scrap/yield loss adjustments and any other recurring costs directly attributable to acquiring the material) [...***...] for administration and carrying costs.
Materials Fee does not include, without limitation, costs associated with establishing, testing or manufacturing components or new materials such as reference standards, reagents, art charges, die costs, mold or tooling

  

					
		  	5	  	***Confidential Treatment Requested

 
costs, plate costs, and packaging equipment change parts. These items will be invoiced to COMPANY at DPT’s cost on a net thirty (30) basis and COMPANY agrees to reimburse DPT for any
such authorized expenditures made on COMPANY’s behalf. 
  

	1.8	Material Safety Data Sheet 

“Material Safety Data Sheet” (“MSDS”) means written or printed material concerning a hazardous chemical which is
prepared in accordance with the regulations promulgated by the Occupational Safety & Health Administration, or any successor entity thereto. 
  

	1.9	Packaging 

“Packaging” means all primary containers, cartons, shipping cases, inserts or any other like material used in packaging, or
accompanying, Product. 
  

	1.10	Product(s) 

“Product(s)” means product(s) (as listed in Schedule A) manufactured, packaged, labeled and/or finished by DPT to meet the
Specifications (as hereinafter defined). 
  

	1.11	Specifications 

“Specifications” means the (i) raw material specifications (including chemical, micro, and packaging specifications);
(ii) sampling requirements (i.e., lab, chemical, and micro); (iii) compounding module, including compounding process and major equipment; (iv) intermediate specifications; (v) packaging module (including packaging procedures,
torque and fill weights); and (vi) finished Product specifications release criteria including DPT’s Acceptable Quality Limits (“AQL’s”). Specifications shall be established and/or amended from time to time upon the written
agreement of both DPT and COMPANY via a Change Control Request (“CCR”) in accordance with Section IX below. 

II—PRODUCT MANUFACTURE AND SUPPLY 
  

	2.1	Manufacture and Purchase 

Subject to the terms and conditions of this Agreement, DPT agrees that it will manufacture for and provide to COMPANY, and COMPANY agrees
that it will purchase from DPT, one hundred percent (100%) of the 

  
 6 

 
COMPANY’s requirements of the Products. COMPANY shall pay DPT for Products according to paragraph 2.8 below. DPT shall manufacture Products in accordance with the Specifications or pursuant
to exceptions approved by COMPANY, and in sufficient quantity to meet COMPANY’s Forecasted Needs for the length of this Agreement. 
  

	2.2	Supply of Materials 

  

	 	(a)	Materials Supplied by COMPANY 

 If COMPANY is to supply any material for manufacture of Products as set forth under this Section, COMPANY shall notify DPT, in writing, specifying which materials it will supply. COMPANY shall provide DPT
with said materials at COMPANY’s expense along with Certificates of Analysis and MSDS sheets relating to same, at a minimum of thirty (30) days prior to DPT’s scheduled production of Product requiring said materials and in sufficient
amounts for DPT’s manufacture of Product but not to exceed quantities necessary to support four (4) months of the most recently supplied Forecasted Needs or the minimum order quantity whichever is greater. COMPANY supplied material in
excess of these amounts shall be either subject to storage fees or returned to COMPANY. All COMPANY supplied material shall be shipped to DPT freight prepaid. In the event COMPANY ships or causes to ship such material freight collect, DPT shall
invoice COMPANY for the cost of the freight plus a reasonable administrative fee which invoice shall be paid promptly upon receipt. DPT is hereby authorized by COMPANY to return any portion of COMPANY supplied material for which no future production
is planned. COMPANY shall be responsible for the quality of all COMPANY-supplied materials. COMPANY shall be responsible for the payment of all personal property and other taxes incident to the storage of COMPANY-owned material at DPT. For each lot
of materials supplied by COMPANY, DPT shall perform the quality control and inspection tests as agreed to in the Specifications unless COMPANY has made arrangements in writing for pre-approved material. DPT shall have the right to reject any
pre-approved material which does not meet the Specifications in accordance with paragraph 2.3 below. DPT warrants that it will maintain, for the benefit of COMPANY, complete and accurate records of the inventory of all such COMPANY-supplied
materials. If requested by COMPANY, DPT will provide to COMPANY a monthly report of ending monthly inventory balance of each COMPANY supplied/owned materials stored at DPT. This reporting will be supplied exclusively on DPT forms. 

  
 7 

	 	(b)	Materials Supplied by DPT 

 DPT shall be responsible for supply, at the expense of COMPANY of all other commodities necessary for the manufacture of Products. All DPT supplied materials will be billed to COMPANY on the respective
invoice for Product, into which the DPT supplied materials was converted, as part of the Materials Fee, and in addition to the Manufacturing Fee, all in accordance with the provisions of paragraph 2.8 below. 

 

	 	(c)	Packaging and Labeling 

 COMPANY shall provide DPT with Specifications (including art proofs) for Packaging and Labeling, and DPT shall purchase, at the expense of COMPANY, Packaging and Labeling in accordance with the
Specifications. 
  

	 	(d)	Additional Charges 

COMPANY shall be responsible for any additional charges (including, but not limited to, items such as brokerage fees, courier expenses,
duty fees payable, etc.) that are incurred in the procurement of any materials and/or Packaging and Labeling components as detailed in the immediately preceding sub-sections (a), (b) and (c); required for the manufacture of the Products,
irrespective of which party to the Agreement is responsible for supplying such items. 
  

	 	(e)	Safety Stock 

 At
least annually, and more frequently depending on business conditions, COMPANY shall determine and inform DPT of the level of safety stock inventory for API and Materials, by Product, that DPT shall hold in its warehouse. COMPANY shall pay for such
safety stock inventory for API and Materials and associated storage fee as agreed upon in writing between the parties. 
  

	2.3	Materials Testing 

 All
materials and packaging supplies shall, when received by DPT, be submitted to analysis and evaluation in accordance with DPT’s SOP’s to determine whether or not said materials meet the Specifications. The

  
 8 

 
cost of all such analyses and evaluations shall be borne by DPT, except as otherwise provided in paragraph 2.2 of this Agreement. DPT agrees to maintain and, if necessary, make available records
of all such analyses and evaluations. 
  

	2.4	Material Safety Data Sheets 

 Prior to DPT’s receipt and testing, and as a condition precedent of any testing or formulation work by DPT pursuant to this Agreement, COMPANY shall provide MSDS sheets to DPT for finished products
and all components necessary for the manufacture of Products. Any components or Products requiring disposal shall be presumed hazardous unless otherwise provided in the MSDS information provided. 

 

	2.5	Commencement of Manufacturing for New Products 

 No later than four (4) months prior to the initial calendar year of a new Product added to this Agreement, COMPANY agrees to notify DPT of its delivery requirements, including firm orders for same,
for the four (4) months and shall provide its Forecasted Needs for the first calendar year in order to ensure timely delivery of Product for initial sale and marketing. 

 

	2.6	Purchase Orders 

  

	 	(a)	Purchase of Products 

 COMPANY agrees to purchase from DPT all Products manufactured for COMPANY by DPT in accordance with COMPANY’s purchase orders or Forecasted Needs to the extent such Products meet the Specifications
or exceptions approved by COMPANY. Products shall be ordered by COMPANY by the issuance of separate, pre-numbered purchase orders in increments of full batches and in minimum order quantities. 

 

	 	(b)	Forecasted Needs 

 COMPANY shall provide DPT with a written, non-binding eighteen (18) month projection with specific data as to its Forecasted Needs. Such Forecasted Needs shall be updated by COMPANY monthly on or
before the 10th day of each calendar month on a rolling
eighteen (18) month basis. It is understood and agreed that with respect to all Forecasted Needs issued to DPT by COMPANY pursuant to the terms hereof, the forecast for the first four (4) months thereof shall constitute a firm order for
Products, regardless of receipt of COMPANY’s actual purchase order. Thereafter, 

  
 9 

 
COMPANY shall provide DPT with a Purchase Order on or before the
10th day of each calendar month. DPT may produce Product
up to thirty (30) days prior to the requested delivery date in order to accommodate fluctuations in production demands. The remaining fourteen (14) months of the Forecasted Needs shall be utilized by DPT for purposes of material
acquisition on behalf of COMPANY and DPT production planning. DPT shall attempt to minimize the material inventory purchased on behalf of COMPANY. Certain materials, however, may have long lead times and/or require a minimum order quantity.
Therefore, DPT may order the chemical and packaging components necessary to support up to six (6) months of COMPANY’s Forecasted Needs, or the applicable minimum order quantity, whichever is greater. Should COMPANY subsequently reduce its
Forecasted Needs, COMPANY will be financially responsible for any material purchased by DPT on COMPANY’s behalf. Any such material which is subsequently rendered in excess of that required to support up to six (6) months of COMPANY’s
Forecasted Needs may be subject to storage and inventory caring fees. DPT may require a deposit for such materials and such materials may also be subject to storage and inventory carrying cost fees. 

 

	 	(c)	Time of Issuance 

COMPANY shall issue written purchase orders for Products to DPT at least one hundred twenty (120) days prior to the requested
delivery dates if the requirements are at or below one hundred twenty-five percent (125%) of the applicable Forecasted Needs, and at least one hundred fifty (150) days prior to the requested delivery dates if the requirements exceed the
Forecasted Needs by more than one hundred twenty-five percent (125%). 
  

	 	(d)	Contents of Purchase Orders 

 COMPANY’s purchase orders shall designate the desired quantities of Products, delivery dates and destinations. This Agreement allows for up to three (3) shipping destinations per batch of
Product. Additional destinations can be accommodated for a shipping preparation fee to be negotiated by DPT and COMPANY. 

  
 10 

	2.7	Rejected Products 

  

	 	(a)	Rejection of Product by COMPANY 

 COMPANY may reject any Product which fails to meet the Specifications, provided that such failure impairs the safety or efficacy of the Product (“Rejected Product”). COMPANY shall, within twenty
(20) days after its receipt of any shipment of Product and related Certificate of Analysis of Product batch (as described in paragraph 5.1 hereof), notify DPT in writing of any claim relating to rejected Product batch and, failing such
notification, shall be deemed to have accepted such Product batch. Such notice to DPT shall specify why the Product batch failed to perform to Specifications. COMPANY shall grant to DPT the right to inspect or test said Product batch. All Products
shall be submitted to inspection and evaluation in accordance with DPT’s SOP’s to determine whether or not said Products meet the Specifications. 
  

	 	(b)	Replacement of Rejected Product 

 As to any Rejected Product pursuant to paragraph 2.7(a) above (including phases of or complete batches of bulk product), DPT shall replace such Rejected Product (in an agreed upon batch order quantity,
but in no event less than full batch increments) promptly after all materials are available to DPT for the manufacture. If requested, DPT shall make arrangements with COMPANY for the return or disposal of Rejected Product. 

 

	 	(c)	Responsibility for Costs 

 For the initial three (3) commercial batches and all validation batches of a Product produced by DPT, or in the event a Rejected Product is due to COMPANY supplied information, formulations or
materials, COMPANY shall bear one hundred percent (100%) of all costs directly related to and invoiced for Rejected Product including cost of destruction of the Rejected Product, which shall be conducted by COMPANY in accordance with all
applicable laws and regulations. Upon the completion of all necessary validation batches and in the event a validated Product is rejected due to DPT’s failure to follow cGMP’s and/or comply with applicable written procedures and such
failure renders the Product unmarketable, DPT shall bear one hundred percent (100%) of the manufacturing fees, costs of all materials (except for the Aptar device) supplied by DPT and cost of destruction. [...***...]. In the

  

					
		  	11	  	***Confidential Treatment Requested

 
event a validated Product does not meet final Specifications and results in a Rejected Product, but such failure is not due to either COMPANY supplied information or DPT’s failure to follow
written procedures, the COMPANY shall bear all Materials Fees with DPT bearing all Manufacturing Fees related to Rejected Product, and with destruction to be paid by the COMPANY. Destruction of Rejected Product shall be in accordance with all
applicable laws and regulations and the party conducting the destruction shall indemnify the other party hereto for any liability, costs or expenses, including attorney’s fees and court costs, relating to a failure to dispose of such Product in
accordance with such laws and regulations. The party conducting the destruction shall also provide to the other party hereto all manifests and other applicable evidence of proper destruction as may be requested by applicable law. 

 

	 	(d)	Resolution of Conflict 

 In the event of a conflict between the test results of DPT and the test results of COMPANY with respect to any shipment of Product batch, a sample of such Product batch shall be submitted by DPT to an
independent laboratory or recognized industry expert acceptable to both parties for testing against the Specifications utilizing the methods set out in the Specifications. The fees and expenses of such laboratory testing shall be borne entirely by
the party against whom such laboratory’s findings are made. If results from the independent laboratory are inconclusive, final resolution will be settled in accordance with paragraph 12.6 (b) below. 

 

	 	(e)	Recalled Product 

In the event (I) any government authority issues a request, directive or administrative order that Product be recalled, or
(ii) a court of competent jurisdiction orders a Product recall, or (iii) the COMPANY reasonably determines that the Product should be recalled, the parties shall take all appropriate corrective actions which are reasonable under the
circumstances. In the event that such recall results solely from the breach of DPT’s warranties under this Agreement, DPT shall be responsible for the administrative expenses of the recall in any case not to exceed [...***...] per recall
incident as well as for the cost of replacing the recalled Product. In the event the recall results from the breach of COMPANY’s warranties under this Agreement, COMPANY shall be responsible for all of the expenses of the recall. For the
purposes of this Agreement, administrative expenses of the recall shall be the expenses of notification, destruction or return of the recalled Product; including 

  

					
		  	12	  	***Confidential Treatment Requested

 
any reasonable out-of-pocket costs incurred by the parties in connection with any corrective action. 
  

	2.8	Product Price 

  

	 	(a)	Manufacturing Fees 

The initial Manufacturing Fees to be paid by COMPANY to DPT are listed in Schedule A. The parties hereto agree that the Manufacturing Fees
set out in Schedule A shall be re negotiated, in good faith, at the beginning of each calendar year. If the parties are unable to agree on a re-negotiated price at least thirty (30) days prior to the start of a new twelve (12) month
period, then this Agreement, effective the first day of January of the new twelve (12) month period, shall continue in force with prices being adjusted to reflect the change in the most recently published monthly “Producer Price Index for
Pharmaceutical Preparation Manufacturing”, issued by the Bureau of Labor Statistics, US Department of Labor (“PPI”), or comparable successor index, in July of the preceding year as compared to the same month of the year prior thereto
until such time as to when price negotiation can be completed. 
 In addition, Manufacturing Fees are based on annual volumes for
Products. DPT reserves the right to re-evaluate Manufacturing Fees at the beginning of the second calendar year (and each calendar year thereafter) in the event that actual volumes differ from those volumes listed in Schedule A. by more than ten
percent (10%). 
 Prices for new Products or new Product sizes, new batch sizes or product configuration changes not initially
included in Schedule A, shall be negotiated and DPT and COMPANY shall arrive at a mutual agreement with respect to prices at the time said new Products or new Product sizes are added to Schedule A. 

If a negotiated price cannot be agreed upon, final pricing for any of the above will be settled in accordance with paragraph 12.6
(b) below. 
  

	 	(b)	Materials Fees 

The Materials Fee to be paid by COMPANY to DPT shall be listed in Schedule A within one hundred twenty (120) days of commencement of
the initial commercial products of the applicable Product. The Materials Fee will be adjusted once annually at the 

  
 13 

 
beginning of each calendar year and Schedule A shall be amended accordingly based on changes in DPT’s standard costs for materials. In the event, however, the cost of a material increases
during any calendar year greater than ten percent (10%), DPT may promptly upon the effective date of such increase adjust its invoice price for said material to COMPANY to compensate for the increase. 

Material Fees for new Products or new Product sizes, new batch sizes or product configuration changes not initially included in Schedule
A, shall be established at the time of first production. 
  

	2.9	Payment 

 Payment for all
deliveries of Product and services shall be made in U.S. Dollars (USD), net thirty (30) days after the date of DPT’s invoice therefor. Invoices shall be generated upon shipment of Product from DPT. Total invoice price shall be equal to the
quantity of Product times the Total Price per unit effective on the date of Product release, as listed in Schedule A. Payments shall be made by certified check, via wire transfer or through other instrument accepted by DPT. Fund transfers by wire
should be made to the following: 
  

			
	 Account name:
	  	[...***...]
	 Account number:
	  	[...***...]
	 Bank name:
	  	Bank of America
	 ABA routing number:
	  	[...***...]
	 SWIFT code (US$)
	  	[...***...]
	 Bank location:
	  	901 Main Street, 8th Floor Dallas, Texas 75202
	 Contact:
	  	[...***...]
		  	[...***...]

  

	2.10	Late Payment 

 A late fee
of one and one-half percent (1.5%) of total invoice can be added each month for late payments. DPT, at its sole discretion, has the right to discontinue COMPANY’s credit on future orders and to put a hold on any production or shipment of
Product if COMPANY’s account is not current. Such hold on production or shipment shall not constitute a breach of this Agreement by DPT. In the event credit is discontinued, a one hundred percent (100%) material deposit paid by COMPANY to
DPT will be required prior to DPT ordering materials. In addition, a fifty percent (50%) Manufacturing Fee deposit will be required prior to DPT 

  

					
		  	14	  	***Confidential Treatment Requested

 
manufacturing any Product and the balance of the invoice must be paid in full prior to shipment. 
  

	2.11	Disposal Costs 

 DPT
reserves the right to invoice COMPANY for all disposal costs, related to manufacture of the Products, unless the disposal relates to a Rejected Product causes by the failure of DPT to follow established written procedures. 

III—SHIPMENT AND RISK OF LOSS 
  

	3.1	Shipment 

 Shipment of
Product shall be in accordance with COMPANY instructions, provided that shipment is made in accordance with all relevant statutory requirements. Product will be shipped to COMPANY or its designee immediately upon release, freight collect. At
COMPANY’s request, DPT may hold Product in DPT’s warehouse for a storage fee. Product held at DPT will be subject to payment as if the product was shipped in accordance with paragraph 2.9 above. If COMPANY requests DPT to make any
miscellaneous small shipments of Product, material, or other items on COMPANY’s behalf, COMPANY agrees to reimburse DPT for any shipping charges incurred. 
  

	3.2	Delivery Terms 

 The
delivery terms of the Products detailed in Schedule A hereof shall be Ex Works (“EXW” Incoterms 2010) DPT’s plant of manufacture, freight collect. Title to, and risk of loss for, Product, shall transfer from DPT to COMPANY when DPT
makes the Product available to COMPANY at its plant of manufacture. COMPANY shall bear all risk of loss, delay, or damage in transit, as well as cost of freight and insurance. 

 

	3.3	Claims 

 The weights,
tares and tests affixed by DPT’s invoice shall govern unless established to be incorrect. Claims relating to quantity, weight and loss or damage to any Product sold under this Agreement shall be waived by COMPANY unless made within thirty
(30) days of receipt of Product by COMPANY. 

  
 15 

 IV—TERM AND TERMINATION 

 

	4.1	Term 

The initial term of this Agreement shall commence on the Effective Date hereof and will continue until
December 31 of the fifth (5th) calendar year
following the Launch Year, unless sooner terminated pursuant to paragraph 4.2 below. This Agreement shall thereafter automatically renew for periods of twenty-four (24) months, unless any party shall give notice to the other to the contrary at
least twenty four (24) months prior to the expiration of the initial term or any renewal term of the Agreement. 
  

	4.2	Termination 

 This
Agreement may be terminated at any time upon the occurrence of either of the following events: 
  

	 	(a)	The failure of either party to comply with its obligations herein, which failure is not remedied within sixty (60) days after written notice thereof.

  

	 	(b)	Notice by either party to the other upon the insolvency or bankruptcy of the other party. 

 

	4.3	Payment on Termination 

In the event of the termination or cancellation of this Agreement for any reason besides DPT termination, and without prejudice to any
other rights and remedies available to DPT hereunder, COMPANY agrees to reimburse DPT the Materials Fee directly ordered for the manufacture of Products based on COMPANY’s Forecasted Needs as well as for work-in-process and finished Products.

  

	4.4	Survival 

 Termination of
this Agreement under paragraph 4.2 or due to expiration or cancellation shall not relieve either party of obligations or liability for breaches of this Agreement incurred prior to or in connection with termination, expiration or cancellation.
Sections VI, VII, IX, X, XI and XII hereof shall survive the termination or cancellation of this Agreement for any reason. 

  
 16 

 V—CERTIFICATES OF ANALYSIS AND MANUFACTURING COMPLIANCE 

 

	5.1	Certificates of Analysis 

DPT shall test each lot of Product purchased pursuant to this Agreement before delivery to COMPANY. Each Certificate of Analysis shall set
forth the items tested, specifications and test results for each lot delivered. DPT shall send one (1) Certificate of Analysis to COMPANY at the time of the release of Product. Extraordinary reporting or documentation, outside this Agreement,
may be subject to an additional charge by DPT. 
  

	5.2	Stability Testing 

 DPT
shall perform its standard stability test program as defined in DPT’s SOP’s or as separately agreed to in accordance with a CCR for each of the Products contained herein. COMPANY shall receive a copy of DPT’s Annual Product Review for
each Product as long as DPT is continuing to produce such Product for COMPANY and for as long as COMPANY’s account is current. If COMPANY elects to perform its own stability testing on Product, COMPANY agrees to provide DPT with a copy of the
results from such testing on an annual basis. 
  

	5.3	Validation Work or Additional Testing 

 It is understood by the parties hereto that the responsibility for any validation work shall be the sole responsibility of COMPANY. The parties agree that for any validation work or additional testing in
connection with the Product, DPT and COMPANY shall enter into a specific written Project Protocol establishing methodology and pricing for such services. It is understood between the parties hereto that if DPT is required by regulatory authority to
perform validation studies or additional testing in order to legitimately continue to engage in the manufacture of the Product for COMPANY and DPT and COMPANY cannot reach an agreement on a written Project Protocol, then DPT shall be under no
obligation to continue the manufacture of the Product affected by said regulation. 
  

	5.4	FDA Inspection 

 DPT shall
advise COMPANY if an authorized agent of the FDA or other governmental agency visits DPT’s manufacturing facility and requests or requires information or changes which specifically pertain to the Products. FDA audit time specific to Products
will be billed to COMPANY from DPT at the then-prevailing QA hourly rate. 

  
 17 

	5.5	Regulatory Filings 

COMPANY agrees to provide DPT with copies of any sections of NDA’s, ANDA’s, 510(k)’s or other regulatory filings applicable
to the Products manufactured and/or tested by DPT, and copies of any changes in or updates of same as they, from time to time, hereafter occur. 
 VI—WARRANTIES 
  

	6.1	Conformity with Specifications 

 DPT warrants that all Products sold pursuant to this Agreement will have been manufactured in accordance with the Specifications for the release of the Product or pursuant to exceptions approved by
COMPANY at the time of manufacture. 
  

	6.2	Compliance with the Act 

COMPANY shall bear sole responsibility for the validity of all test methods and appropriateness of all Specifications. In addition,
COMPANY shall bear sole responsibility for all regulatory approvals, filings, and registrations and adequacy of all validation, stability, and preservative efficacy studies. COMPANY further warrants that it has obtained any and all necessary
approvals from all applicable regulatory agencies necessary to manufacture and distribute all Products under this Agreement. 
  

	6.3	Conformity with FDA regulations and cGMP’s 

 Subject to the provisions set forth in paragraph 6.2 and 6.4 hereof, DPT warrants that all Products shall have been manufactured by DPT in compliance with applicable FDA regulations and current Good
Manufacturing Practices as that term is defined under the Act. 
  

	6.4	Compliance of Packaging and Labeling with Laws and Regulations 

 COMPANY warrants that all Labeling copy and artwork approved, designated or supplied by COMPANY shall be in compliance with all applicable laws and governmental regulations. Compliance with all federal,
state, and local laws and regulations concerning Packaging and Labeling shall be the sole responsibility of COMPANY, provided that DPT purchases such Packaging and Labeling as provided in paragraph 2.2 (c) hereof. COMPANY hereby represents and
warrants to DPT that all COMPANY designated formulas, components and artwork related to the Product do not violate or infringe any patent, copyright or trademark laws, 

  
 18 

 
and agrees to indemnify DPT, its employees, officers, directors and representatives for any claim, loss or damage including reasonable attorney’s fees paid or incurred by any of them in
connection therewith. 
  

	6.5	Access to DPT’s Facilities 

 COMPANY shall have access to DPT’s facilities at a mutually agreeable time for the sole purpose of auditing DPT’s compliance with current Good Manufacturing Practices and the Act. Such access
shall in no way give COMPANY the right to any of DPT’s confidential or proprietary information. Further, such audits shall normally be limited to every eighteen (18) months and three (3) employees of COMPANY who are subject to the
same requirements of confidentiality as COMPANY. 
  

	6.6	Disclaimer 

 DPT AND
COMPANY MAKE NO WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE PRODUCT, LABELING OR PACKAGING; EXCEPT AS DETAILED HEREIN. ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR
A PARTICULAR PURPOSE ARE HEREBY DISCLAIMED. IN NO EVENT WILL DPT BE LIABLE FOR ANY LOSS OF PROFITS, LOSS OF USE, BUSINESS INTERRUPTION, COST OF COVER, OR INDIRECT, SPECIAL, INCIDENTAL, OR CONSEQUENTIAL DAMAGES OF ANY KIND IN CONNECTION WITH OR
ARISING OUT OF THE PERFORMANCE OF THIS AGREEMENT, WHETHER ALLEGED AS A BREACH OF CONTRACT OR TORTIOUS CONDUCT, INCLUDING NEGLIGENCE, EVEN IF DPT HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. DPT’S LIABILITY UNDER THIS AGREEMENT FOR FIRST
PARTY DAMAGES OF ANY KIND, INCLUDING, WITHOUT LIMITATION, RESTITUTION, WILL NOT EXCEED, THE AMOUNT OF MANUFACTURING FEES PAID BY COMPANY TO DPT UNDER THIS AGREEMENT UP TO A MAXIMUM AMOUNT OF [...***...]. 

VII—FORCE MAJEURE 
 Failure of either party to perform its obligations under this Agreement shall not subject such party to any liability to the other if such failure is caused by acts such as, but not limited to, acts of
God, acts of terrorism, fires, explosion, flood, drought, war, riot, sabotage, embargo, strikes, compliance with any court order or regulation of any government entity 

  

					
		  	19	  	***Confidential Treatment Requested

 
acting with color of right or by any other cause beyond the reasonable control of the parties, whether or not foreseeable. 
 VIII—CHANGES TO PROCESS OR PRODUCT 
  

	8.1	Changes by COMPANY 

 If
COMPANY at any time requests a change to Product and DPT agrees such change is reasonable with regard to Product manufacture; (i) such change shall be incorporated within the Master Batch Record and/or Specifications via a written CCR reviewed
and agreed upon by both DPT and COMPANY; (ii) The parties shall adjust the price of Product, if necessary, and Schedule A shall be amended accordingly; and (iii) COMPANY shall pay DPT for the costs associated with such change including,
but not limited to, any additional development or validation work required, charged at DPT’s then-prevailing R&D rates in accordance with Section XI contained herein. 

 

	8.2	Changes by DPT 

 DPT
agrees that any changes developed by DPT, which may be incorporated into the Product shall require the written approval of COMPANY via a CCR prior to such incorporation. At the time of such incorporation, such changes shall become part of the
Specifications. It is also agreed that any regulatory filings incident to any such change shall be the sole responsibility of COMPANY. 
  

	8.3	Changes by Regulatory Authorities 

 The parties agree that any changes required by regulatory authority, shall be incorporated into the Product as evidenced by the written approval of COMPANY via a CCR prior to such incorporation. At the
time of such incorporation, such changes shall become part of the Specifications. If DPT is required by regulatory authority to perform validation studies for purposes of validating new manufacturing process or cleaning procedures or new material
and finished Product assay procedures with respect to Product in order to continue to engage in the manufacture of said Product for COMPANY, such studies shall be conducted in accordance with paragraph 5.3 herein. Any costs to DPT resulting from the
operation of this paragraph shall be reimbursed by COMPANY. 

  
 20 

	8.4	Obsolete Inventory 

 Any
COMPANY-specific inventory including, but not limited to, materials, work-in-process, and Products rendered obsolete as a result of formula, artwork or packaging changes requested by COMPANY or by changes required by regulatory authority shall be
reimbursed to DPT by COMPANY at DPT’s Materials Fee. At such time and unless otherwise instructed by COMPANY agreed by DPT, DPT will ship the obsolete inventory to COMPANY for destruction by COMPANY. COMPANY shall bear one hundred percent
(100%) of all shipping and destruction costs related to said obsolete inventory. The destruction shall be in accordance with all applicable laws and regulations and COMPANY shall indemnify DPT for any liability, costs or expenses, including
attorney’s fees and court costs, relating to COMPANY’s failure to dispose of such inventory in accordance with such laws and regulations. COMPANY shall also provide DPT with all manifests and other applicable evidence of proper destruction
as may be requested by DPT or required by applicable law. If DPT does not receive disposition instructions from COMPANY within ninety (90) days from date of obsolescence, obsolete inventory remaining at DPT’s facilities shall be subject to
a deposit covering the standard cost of the obsolete inventory and storage fees. 
 IX—CONFIDENTIAL INFORMATION

  

	9.1	Confidential Information 

  

	 	(a)	Obligations of Confidentiality 

 All confidential information furnished by COMPANY to DPT, or by DPT to COMPANY, during the term of this Agreement, relating to the subject matter hereof, shall be kept confidential by the party receiving
said confidential information, except for purposes authorized by this Agreement, and shall not be disclosed to any person or firm, unless previously authorized in writing to do so, for a period of not less than five (5) years following the date
of disclosure. The party receiving said confidential information may, however, disclose the same to its responsible officers and employees who require said information for the purposes contemplated by this Agreement, provided that said officers and
employees shall have assumed like obligations of confidentiality. It is understood that all confidential information provided by either party shall be identified or marked as such. Any oral communications which are to be considered confidential
shall be reduced to writing and identified as confidential within thirty (30) days after disclosure. 

  
 21 

	 	(b)	Exceptions 

 Any
other provisions hereof to the contrary notwithstanding, it is expressly understood and agreed by the parties hereto that the obligations of confidence and nonuse herein assumed shall not apply to any information which: 

 

	 	(1)	is at the time of disclosure or thereafter so becomes a part of the public domain; or 

 

	 	(2)	was otherwise in the receiving party’s lawful possession prior to disclosure as shown by its written record; or 

 

	 	(3)	is hereafter disclosed to the receiving party by a third party purporting not to be in violation of an obligation of confidentiality to the disclosing party relative to
said information; or 

  

	 	(4)	is by mutual agreement of the parties hereto released from a confidential status; or 

 

	 	(5)	is required to be disclosed pursuant to regulatory or legal requirements. 

 

	 	(c)	DPT Business Model 

COMPANY acknowledges that as a contract manufacturing organization, DPT’s business involves the application of its expertise,
technology and know-how to numerous pharmaceutical and other products and that DPT retains the right (subject to its obligations under the applicable confidentiality provision or agreement) to apply such expertise, technology and know-how to a
variety of products or services. 
  

	9.2	Trademarks and Trade Names 

  

	 	(a)	Each party hereby acknowledges that it does not have, and shall not acquire any interest in any of the other party’s trademarks or trade names unless otherwise
expressly agreed. 

  

	 	(b)	Each party agrees not to use any trade names or trademarks of the other party, except as specifically authorized by the other party in writing both as to the names or
marks which may be used and as to the manner and prominence of use. 

  
 22 

	9.3	Inventions and Patents 

Section 8 regarding Collaborative Efforts of the Research and Development Services Agreement between DPT and COMPANY dated
April 17, 2009, is hereby incorporated in its entirety by its reference and shall remain in effect for the term of this Agreement. 
 X—RESEARCH & DEVELOPMENT SERVICES 
  

	10.1	R&D Services 

  

	 	(a)	Research Products 

From time to time, COMPANY may request, in writing, that DPT evaluate, develop, manufacture, test and/or provide price quotations for
certain new items which may become Products (hereinafter referred to as “Research Products”) on behalf of COMPANY. If DPT agrees to perform such services, DPT shall so notify COMPANY within sixty (60) days of its receipt of
COMPANY’s request. To the extent that DPT agrees to perform any services hereunder for COMPANY, DPT shall only be obligated to act in good faith and to use reasonable efforts to accomplish the desired results as outlined in a mutually agreed
upon Project Protocol. Nothing herein shall obligate DPT to achieve any specific results and DPT makes no warranties or representations that it will be able to achieve the desired results. 

 

	 	(b)	Project Protocol 

Should DPT agree to perform any services hereunder, DPT shall submit a written development proposal in the form of a Project Protocol to
COMPANY identifying DPT’s best estimate of the development costs. This estimate shall include, but not be limited to, labor hours for development, testing, scale up, stability, report writing, etc., as well as all reasonably foreseeable
associated tasks and expenses. If this estimate is acceptable to COMPANY and COMPANY so notifies DPT by approving the Project Protocol in writing, DPT shall begin work as outlined in the Protocol. It is understood between both parties that during
any development project unforeseen circumstances may evolve, including, but not limited to, termination of any further activity due to unacceptable results, significant reevaluation due to marginal results, etc. DPT will promptly notify COMPANY of
any such unforeseen circumstances before proceeding at which time either COMPANY or DPT may terminate the project or mutually agree to amend or completely revise the Project Protocol. In the case where the 

  
 23 

 
project is terminated or revised, COMPANY will be obligated to pay for all of the work performed by DPT up to that point. 

 

	 	(c)	Costs 

 Material
costs involved will be billed to COMPANY at DPT’s cost [...***...] for administration and carrying costs. The foregoing development costs shall be paid to DPT in accordance with DPT’s standard invoicing procedures regardless of
whether DPT is able to accomplish the results which COMPANY requested. All invoices shall be paid by COMPANY in accordance with paragraph 2.7 above. On or before sixty (60) days of the development of a finished product prototype (which shall
include final primary container selection filled with Research Product), DPT will provide an estimate of the Manufacturing Fee. DPT may also provide an estimate of the Materials Fee, should specifications be known for these items at such time. The
estimated Manufacturing Fee shall automatically be adjusted annually based upon CPI adjustments pending commencement of Production. 
  

	 	(d)	Obsolete Inventory 

Any COMPANY-specific inventory including, but not limited to, materials, bulk Research Product, waste by-products, testing supplies,
stability samples, work-in-process, and finished goods rendered obsolete at the conclusion, revision or termination of the development project shall be shipped to COMPANY or, at DPT election destroyed by DPT. COMPANY shall bear one hundred percent
(100%) of all destruction costs related to said obsolete inventory. The destruction shall be in accordance with all applicable laws and regulations and COMPANY shall indemnify DPT for any liability, costs or expenses, including attorney’s
fees and court costs, relating to COMPANY’s failure to dispose of such inventory in accordance with such laws and regulations. COMPANY shall also provide DPT with all manifests and other applicable evidence of proper destruction as may be
requested by DPT or required by applicable law. DPT shall notify COMPANY of its intention to dispose of inventory. If DPT does not receive disposition instructions from COMPANY within ninety (90) days from date of obsolescence, obsolete
inventory remaining at DPT’s facilities shall be subject to storage fees. 

  

					
		  	24	  	***Confidential Treatment Requested

 XI—INDEMNIFICATION 

 

	11.1	Indemnification by DPT 

Subject to paragraph 6.6 above, DPT will indemnify and hold COMPANY harmless against any and all liability, damage, loss, cost, or expense
(including reasonable attorney’s fees) resulting from any third party claims made or suits brought against COMPANY which arise from DPT’s breach of its warranties set forth in Section VI hereof, up to the amount of insurance coverage as
provided for herein. 
  

	11.2	Insurance by DPT 

 While
this Agreement is in full force and effect, DPT shall furnish COMPANY with evidence of Commercial General Liability insurance (including endorsements for Products and Contractual Liability) coverage affording a minimum amount of [...***...]
per occurrence combined single limit, bodily injury/property damage and [...***...] aggregate liability limits. Such evidence of insurance coverage can be in the form of the original policy or a Certificate of Insurance which shall name the
COMPANY as an additional insured and provided that DPT has assumed the liability as provided for herein. 
  

	11.3	Indemnification by COMPANY 

COMPANY will indemnify and hold DPT harmless against any and all liability, damage, loss, cost or expense (including reasonable
attorney’s fees) resulting from any third party claims made or suits brought against DPT which are related to the breach of any of COMPANY’s warranties provided for herein or which arise out of the promotion, distribution, use, testing or
sales of Products, including, without limitation, any claims, express, implied or statutory, made as to the efficacy, safety, or use to be made of Products, and claims made by reason of any Product Labeling or any Packaging containing Product
(provided such packaging and Labeling was purchased by DPT as provided in paragraph 2.2 (c) hereof), unless such liability, damage, loss or expense is caused by the breach of DPT’s warranties under Section VI hereof. 

 

	11.4	Insurance by COMPANY 

While this Agreement is in full force and effect, COMPANY shall furnish DPT with evidence of Commercial General Liability insurance
(including endorsements for Products and Contractual Liability) coverage affording a minimum amount of [...***...] per occurrence combined single limit, bodily injury/property damage and

  

					
		  	25	  	***Confidential Treatment Requested

 
[...***...] aggregate liability limits. Such evidence of insurance coverage can be in the form of the original policy or a Certificate of Insurance which shall name DPT as an additional
insured and provide that COMPANY has assumed the liability as provided for herein. 
  

	11.5	Stacking of Insurance 

Neither COMPANY nor DPT intend for their respective insurance policies to stack on top of each other. To that end, both parties agree that
if a loss is incurred, for which DPT has an obligation under Section 11.1 to indemnify COMPANY hereunder, DPT’s policies will be triggered and DPT will defend COMPANY under the additional insured endorsement, Furthermore, if a loss is
incurred for which Company has an obligation under Section 11.3 to indemnify DPT hereunder, then COMPANY’s policies will be triggered and COMPANY will defend DPT under the additional insured endorsement. 

 

	11.6	Patent and Other Intellectual Property Rights 

  

	 	(a)	Warranty by COMPANY 

COMPANY warrants that use of Products or sales of Products will not infringe any patent or other proprietary rights and that COMPANY will
indemnify, defend and hold DPT harmless from any damage, judgment, loss, cost or other reasonable expense (including reasonable attorney’s fees) arising from claims that Products or the use of the Product names and any other trademarks, trade
names, or trade dress used by COMPANY in connection with Products infringes patent or other proprietary rights of a third party. 
  

	 	(b)	Warranty by DPT 

DPT shall indemnify and hold COMPANY harmless from all costs, damages and expense (including reasonable attorney’s fees) arising out
of any suit or action brought against COMPANY based upon a claim that any process or technical data furnished or utilized by DPT infringes any patent or other proprietary rights. 

 

	11.7	Conditions of Indemnification 

 If either party expects to seek indemnification from the other under paragraphs 11.1 or 11.3 hereof, it shall promptly give notice to the other 

  

					
		  	26	  	***Confidential Treatment Requested

 
party of any such claim or suit threatened, made or filed against it which forms the basis for such claim of indemnification and shall cooperate fully with the other party in the defense of all
such claims or suits. No settlement or compromise shall be binding on a party hereto without its prior written consent. 

XII—GENERAL PROVISIONS 
  

	12.1	Notices 

 Any notices
permitted or required by this Agreement shall be sent by certified or registered mail with a copy by fax and shall be effective the earlier of the date received or three (3) days after deposit in the U.S. mail, if sent and addressed as follows
or to such other address as may be designated by either party in writing: 
  

			
	 If to DPT:
	  	DPT Lakewood, LLC
		  	c/o: DPT Laboratories, Ltd.
		  	Attention: President
		  	318 McCullough Ave.
		  	San Antonio, Texas 78215
		  	Fax: (210) 227-6132
		  	with a copy to the General Counsel’s Office

  

			
	 If to COMPANY:
	  	Insys Therapeutics
		  	10220 South 51st Street, Suite 2
		  	Phoenix, AZ 85044
		  	Attention: President
		  	Fax: (602) 910-2627
		  	with a copy to the General Counsel’s Office

  

	12.2	Entire Agreement; Amendment 

 The parties hereto acknowledge that this document sets forth the entire agreement and understanding of the parties and supersedes all prior written or oral agreements or understandings with respect to the
subject matter hereof, and shall supersede any conflicting portions of DPT’s quotation, acknowledgment and invoice forms and COMPANY’s Purchase Order and other written forms. No modification of any of the terms of this Agreement, or any
amendments thereto, shall be deemed to be valid unless in writing and signed by the party against whom enforcement is sought. No course of dealing or usage of trade shall be used to modify the terms and conditions herein. 

  
 27 

	12.3	Waiver 

 No waiver by
either party of any default shall be effective unless in writing, nor shall any such waiver operate as a waiver of any other default or of the same default on a future occasion. 

 

	12.4	Obligations to Third Parties 

 Each party warrants and represents that proceeding herein is not inconsistent with any contractual obligations, express or implied, undertaken with any third party. 

 

	12.5	Assignment 

 This
Agreement shall be binding upon and inure to the benefit of the successors or permitted assigns of each of the parties and may not be assigned or transferred by either party without the prior written consent of the other, which consent will not be
unreasonably withheld. No such assignment shall release the original party hereto from its duties and obligations under this Agreement. 
  

	12.6	Governing Law and Arbitration 

  

	 	(a)	Governing Law 

 The
validity, interpretation and effect of this Agreement shall be governed by and construed under the substantive laws of the State of New Jersey, excluding any conflicts of law provisions contained therein. 

 

	 	(b)	Arbitration 

  

	 	(i)	 ANY DISPUTE, CLAIM OR CONTROVERSY ARISING FROM OR RELATED IN ANY WAY TO THIS AGREEMENT OR THE INTERPRETATION, APPLICATION, BREACH, TERMINATION OR
VALIDITY THEREOF, INCLUDING ANY CLAIM OF INDUCEMENT OF THIS AGREEMENT BY FRAUD OR OTHERWISE, WILL BE SUBMITTED FOR RESOLUTION TO ARBITRATION PURSUANT TO THE COMMERCIAL ARBITRATION RULES THEN PERTAINING OF THE CENTER FOR PUBLIC RESOURCES
(“CPR”), EXCEPT WHERE THOSE RULES CONFLICT WITH THESE PROVISIONS, IN WHICH CASE THESE PROVISIONS CONTROL. SUCH ARBITRATION SHALL BE HELD IN (I) COMPANY’S HOME COUNTY, IF THE DEMAND FOR

  
 28 

	 	ARBITRATION IS INITIATED BY DPT OR (II) OCEAN COUNTY, NEW JERSEY, IF THE DEMAND FOR ARBITRATION IS INITIATED BY COMPANY. 

 

	 	(ii)	The panel shall consist of three arbitrators chosen from the CPR Panels of Distinguished Neutrals each of whom is a lawyer specializing in business litigation with at
least 15 years experience with a law firm of over 25 lawyers or was a judge of a court of general jurisdiction. In the event the aggregate damages sought by the claimant are stated to be less than $5 million, and the aggregate damages sought by the
counterclaimant are stated to be less than $5 million, and neither side seeks equitable relief, then a single arbitrator shall be chosen, having the same qualifications and experience specified above. 

 

	 	(iii)	The parties agree to cooperate (1) to obtain selection of the arbitrator(s) within 30 days of initiation of the arbitration, (2) to meet with the
arbitrator(s) within 30 days of selection and (3) to agree at that meeting or before upon procedures for discovery and as to the conduct of the hearing which will result in the hearing being concluded within no more than 9 months after
selection of the arbitrator(s) and in the award being rendered within 60 days of the conclusion of the hearings, or of any post-hearing briefing, which briefing will be completed by both sides within 20 days after the conclusion of the hearings. In
the event no such agreement is reached, the CPR will select arbitrator(s), allowing appropriate strikes for reasons of conflict or other cause and three peremptory challenges for each side. The arbitrator(s) shall set a date for the hearing, commit
to the rendering of the award within 60 days of the conclusion of the evidence at the hearing, or of any post-hearing briefing (which briefing will be completed by both sides in no more than 20 days after the conclusion of the hearings), and provide
for discovery according to these time limits, giving recognition to the understanding of the parties hereto that they contemplate reasonable discovery, including document demands and depositions, but that such discovery be limited so that the time
limits specified herein may be met without undue difficulty. In no event will the arbitrator(s) allow either side to obtain more than a total of 40 hours of deposition testimony from all witnesses, including both fact and expert witnesses. In the
event multiple hearing days are required, they will be scheduled consecutively to the greatest extent possible. 

  
 29 

	 	(iv)	The arbitrator(s) shall render an opinion setting forth findings of fact and conclusions of law with the reasons therefor stated. A transcript of the evidence adduced
at the hearing shall be made and shall, upon request, be made available to either party. 

  

	 	(v)	To the extent possible, the arbitration hearings and award will be maintained in confidence. 

 

	 	(vi)	Any court of competent jurisdiction may enter judgment upon any award. In the event the panel’s award exceeds $5 million in monetary damages or includes or
consists of equitable relief, then the court shall vacate, modify or correct any award where the arbitrators’ findings of fact are clearly erroneous, and/or where the arbitrators’ conclusions of law are erroneous; in other words, it will
undertake the same review as if it were a federal appellate court reviewing a district court’s findings of fact and conclusions of law rendered after a bench trial. An award for less than $5 million in damages and not including equitable relief
may be vacated, modified or corrected only upon the grounds specified in the Federal Arbitration Act. 

  

	 	(vii)	Each party has the right before or during the arbitration to seek and obtain from the appropriate court provisional remedies such as attachment, preliminary injunction,
replevin, etc. to avoid irreparable harm, maintain the status quo, or preserve the subject matter of the arbitration. 

  

	 	(viii)	EACH PARTY HERETO WAIVES ITS RIGHT TO TRIAL OF ANY ISSUE BY JURY. 

  

	 	(c)	Mediation 

  

	 	(i)	 ANY DISPUTE, CONTROVERSY OR CLAIM ARISING OUT OF OR RELATED TO THIS AGREEMENT, OR THE INTERPRETATION, APPLICATION, BREACH, TERMINATION OR VALIDITY
THEREOF, INCLUDING ANY CLAIM OF INDUCEMENT BY FRAUD OR OTHERWISE, WHICH CLAIM WOULD, BUT FOR THIS PROVISION, BE SUBMITTED TO ARBITRATION SHALL, BEFORE SUBMISSION TO ARBITRATION, FIRST BE MEDIATED THROUGH NON-BINDING MEDIATION. SUCH MEDIATION SHALL
BE HELD IN (I) COMPANY’S HOME COUNTY, IF THE DEMAND FOR MEDIATION IS INITIATED BY DPT OR 

  
 30 

	 	 
(II) OCEAN COUNTY, NEW JERSEY, IF THE DEMAND FOR MEDIATION IS INITIATED BY COMPANY AND SHALL BE ATTENDED BY A SENIOR EXECUTIVE WITH AUTHORITY TO RESOLVE THE DISPUTE FROM EACH OF THE OPERATING
COMPANIES THAT ARE PARTIES. 

  

	 	(ii)	After written notice of any dispute or controversy arising out of or related to the Agreement, or the interpretation, application, breach, termination or validity
thereof and Written Demand for Mediation (the “Written Demand for Mediation”), the parties shall promptly confer within thirty (30) days in an effort to select a mediator by mutual agreement. In the absence of such an agreement within
sixty (60) days of the date of the Written Demand for Mediation by either of the parties, the mediator shall be selected by the party making the demand for mediation. In the event that the party that has not made the Written Demand for
Mediation refuses to participate in the mediation process for any reason, or mediation is not scheduled within ninety (90) days of the Written Demand for Mediation for any reason, then the part that made the Written Demand for Mediation shall
have the absolute right to proceed to arbitration pursuant to paragraph 12.6(b) of this Agreement. 

  

	 	(iii)	The mediator shall confer with the parties to design procedures to conclude the mediation within no more than 45 days after initiation. Under no circumstances shall the
commencement of arbitration under Section 18(b) above be delayed more than 45 days by the mediation process specified herein. 

  

	 	(iv)	Each party agrees to toll all applicable statutes of limitation during the mediation process and not to use the period or pendency of the mediation to disadvantage the
other party procedurally or otherwise. No statements made by either side during the mediation may be used by the other during any subsequent arbitration. 

  

	 	(v)	Each party has the right to pursue provisional relief from any court, such as attachment, preliminary injunction, replevin, etc., to avoid irreparable harm, maintain
the status quo, or preserve the subject matter of the arbitration, even though mediation has not been commenced or completed 

  
 31 

	 	(d)	Costs 

 The costs
of arbitration and/or mediation, including reasonable attorney’s fees, shall be borne by the losing party. 
  

	12.7	Severability 

 In the
event that any term or provision of this Agreement shall violate any applicable statute, ordinance, or rule of law in any jurisdiction in which it is used, or otherwise be unenforceable, such provision shall be ineffective to the extent of such
violation without invalidating any other provision hereof. 
  

	12.8	Headings, Interpretation 

  

	 	The	headings used in this Agreement are for convenience only and are not a part of this Agreement. 

 

	12.9	Counterparts 

 This
Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same original. 
  

	12.10	Independent Contractor 

In performing its services hereunder, DPT shall act as an independent contractor. 

 

	12.11	Export/Import Laws and Regulations 

 This Agreement is subject to any restrictions concerning the import or export of Product, active pharmaceutical ingredient, chemical or packaging components (or related technical information or data) to
or from the United States as well as the laws and regulations of any other country involved in the import or export of such Product, active pharmaceutical ingredient, chemical or packaging components (or related technical information or data).
COMPANY acknowledges that it shall be solely and exclusively responsible for the preparation of all import and export documentation and compliance with all import and export laws of the United States as well as the laws and regulations of any other
country involved in the import or export of such Product, active pharmaceutical ingredient, chemical or packaging components (or related technical information or data); except as otherwise agreed by the parties in writing. COMPANY shall indemnify
and hold DPT, its officers, directors, employees, shareholders and affiliates harmless, from any and all claims, 

  
 32 

 
losses, liabilities, damages, fines, penalties, costs and expenses (including reasonable attorneys’ fees) arising from, or related to, any breach by COMPANY of its obligations under this
provision. COMPANY shall be the importer or exporter of record for all such import or export activities. COMPANY shall cooperate with DPT as reasonably necessary to permit DPT to comply with the laws and regulations of the United States and any
other country relating to the control of import or export of Product, active pharmaceutical ingredient, chemical or packaging components (or related technical information or data). 

IN WITNESS WHEREOF, the parties hereto have each caused this Agreement to be executed by their duly authorized officers as of the
date first above written. 
  

									
		 	 INSYS THERAPEUTICS
	 		 		  	DPT LAKEWOOD, LLC
					
	 By:
	 	 /s/    Michael
Babich        
	 		 	 By:
	  	/s/    Paul Johnson        
					
	 Its:
	 	 President and CEO
	 		 	 Its:
	  	President and COO

  
 33 

 Schedule A 
 SCHEDULE A – 2011 
 Insys

 Therapeutics 
  

																											
	 PRODUCT

NUMBER
	  	 PRODUCT
 DESCRIPTION
	  	MINIMUM
ANNUAL
VOLUME	 	  	BATCH
SIZE	 	  	UNIT
BATCH
YIELD	 	  	MFG.
FEE	 	  	MATERIAL
FEE	 	  	TOTAL
UNIT
FEE	 
	 [...***...]

[...***...]

[...***...]

[...***...]

[...***...]
	  	
Fentanyl Sub lingual spray
 [...***...]
	  	 	[...***...]	  	  	 	[...***...]	  	  	 	[...***...]	  	  	 	[...***...]	  	  	 	[...***...]	  	  	 	[...***...]	  
	 [...***...]

[...***...]

[...***...]

[...***...]

[...***...]
	  	
Fentanyl Sub lingual spray
 [...***...]
	  	 	[...***...]	  	  	 	[...***...]	  	  	 	[...***...]	  	  	 	[...***...]	  	  	 	[...***...]	  	  	 	[...***...]	  
	 [...***...]

[...***...]

[...***...]

[...***...]

[...***...]
	  	
Fentanyl Sub lingual spray
 [...***...]
	  	 	[...***...]	  	  	 	[...***...]	  	  	 	[...***...]	  	  	 	[...***...]	  	  	 	[...***...]	  	  	 	[...***...]	  
	 	  	 	  	 	[...***...]	  	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 

  

	1)	Manufacturing and Materials Fee’s are based on [...***...] 

	2)	Effective date for above Fees is [...***...] through [...***...] 

	3)	[...***...] 

	4)	[...***...] 

	5)	[...***...] 

	6)	Pricing does not include [...***...] 

	7)	Materials Fee will be based on [...***...] 

 Initials/Date Insys Therapeutics:    /s/ MB 6/1/11 
 Initials/Date DPT Laboratories:    /s/ PJ 5/31/11] 

  

					
		  	34	  	***Confidential Treatment RequestedSupply Agreement

 Exhibit 10.15 
 ***Text Omitted and Filed Separately 
 with the Securities and Exchange
Commission. 
 Confidential Treatment Requested 
 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 230.406 

Index of Contents 
  

							
	1.	  	DEFINITIONS	  	 	1	  
	2.	  	MANUFACTURE AND SALE	  	 	3	  
	3.	  	DEFINITIONS	  			
	4.	  	RIGHT OF FIRST REFUSAL	  	 	4	  
	5.	  	FORECASTS, ORDERS AND DELIVERY	  	 	5	  
	6.	  	PRICES AND PAYMENT	  	 	6	  
	7.	  	REGULATORY RESPONSIBILITY	  	 	7	  
	8.	  	QUALITY CONTROL REQUIREMENTS	  	 	8	  
	9.	  	REJECTION	  	 	9	  
	10.	  	WARRANTY	  	 	10	  
	11.	  	INDEMNIFICATION	  	 	12	  
	12.	  	REPRESENTATIONS	  	 	12	  
	13.	  	TERM AND TERMINATION	  	 	13	  
	14.	  	MISCELLANEOUS	  	 	14	  
	EXHIBIT A: DEVICE SPECIFICATION	  	 	18	  
	EXHIBIT B: SELLER CERTIFICATE OF ANALYSIS + SELLER STANDARD SPECIFICATION	  	 	19	  
	EXHIBIT C: PURCHASE PRICE	  	 	20	  
	EXHIBIT D: [...***...]	  	 	23	  
	EXHIBIT E: STANDARD TERMS AND CONDITIONS	  	 	25	  
	EXHIBIT F: STANDARD PACKAGING AND PACKING SPECIFICATIONS	  	 	27	  

  

					
		  	i	  	***Confidential Treatment Requested

 SUPPLY AGREEMENT 

This SUPPLY AGREEMENT (the “Agreement”), effective as of the seventh day of March, 2011 (the “Effective
Date”), is made and entered into by and between Insys Therapeutics, Inc., a Delaware corporation having its principal place of business at 10220 South 51st St., Suite 2, Phoenix, AZ 85044-5231 (hereinafter called
“PURCHASER”) and Aptargroup, Inc., a Delaware corporation having its principal place of business at 475 West Terra Cotta, Suite E, Crystal Lake, IL, 60014-9695 (hereinafter called “SELLER”). PURCHASER and SELLER
being hereinafter called individually the “Party” and collectively the “Parties”. 
 WHEREAS SELLER is engaged
in the development and manufacture of dispensing systems for medical use, with particular reference to nasal and oral devices; 
 WHEREAS
PURCHASER desires to purchase the Device (defined below) for Purchaser’s own use with Drug Product (defined below), subject to the terms and conditions herein; and 
 WHEREAS SELLER desires to sell the Device to PURCHASER subject to the terms and conditions herein. 

NOW, THEREFORE, in consideration of the mutual promises and covenants contained herein, the Parties agree as follows: 

 

	1.	DEFINITIONS 

 As used herein, the
following terms and expressions shall have the meanings set forth below: 
  

	 	1.1	“Affiliate” means any person or entity that directly or indirectly through one or more intermediaries’ Controls, is Controlled by, or is under
common Control with a Party, where “Control” means the direct or indirect, legal or beneficial ownership of more than fifty percent (50%) of the outstanding voting rights in a company. 

 

	 	1.2	“cGMP” means the current good manufacturing practices stipulated or promulgated from time to time by the Regulatory Authorities that are applicable to
the manufacture of the Device. 

  

	 	1.3	“Cumulative Yearly Quantity” means the cumulative total Minimum Yearly Quantity amount of the Device PURCHASER must procure from the SELLER to maintain
pricing levels as defined in Exhibit C. 

  

	 	1.4	“Development Activities” means all research and development activities related to the development of a drug (including alternative delivery systems)
through preclinical and clinical stages. 

  

	 	1.5	“Device” means the device described in the Device Specifications. 

  
 1 

	 	1.6	“Device Equipment” means the moulds and assembly machines required at SELLER’s premises to manufacture the Device in commercial quantities.

  

	 	1.7	“Device Equipment Contribution” means the PURCHASER’s [...***...] reimbursement of research and development costs of SELLER related to, but
not limited to, the Device Equipment as described in Exhibit C. 

  

	 	1.8	“Design” means any combination of outer shape and color of the Device. 

 

	 	1.9	“Device Specifications” means the Device’s specifications as described in Exhibit A. 

 

	 	1.10	“Drug Product” means the sublingual formulation of Fentanyl owned by PURCHASER and currently known as “Fentanyl SL”.

  

	 	1.11	“Effective Date” means the day inserted on the introductory clause of this Agreement. 

 

	 	1.12	“FDA Approval” means the approval of the new drug application (NDA) for the Finished Product by the Food and Drug Administration in the United States
of America (FDA). 

  

	 	1.13	 “Fentanyl” means the compound with molecular formula C22H28
N2O and IUPAC name N-(1-2-phenlyethyl)-4-piperidinyl)-N-phenylpropanamide . 

  

	 	1.14	“Fentanyl Market” means the total unit sales of all non-extended release pharmaceutical products containing Fentanyl as an active pharmaceutical
ingredient. 

  

	 	1.15	“Finished Product” means the Drug Product in conjunction with the Device. 

 

	 	1.16	“Intellectual Property” means all present and future intellectual property rights and information, material and trade secrets that relate to the Device
or the Drug Product, as the case may be, whether or not patentable, including any know-how. 

  

	 	1.17	“Marketing Approval” means, with respect to any country, the approval of any marketing application for the Finished Product by the appropriate
Regulatory Authority in such country, including (a) FDA Approval, (b) approval of a marketing authorization application by the EU Medicines Agency and (c) approval of other product registration application with respect to any other
territory. 

  

	 	1.18	“Minimum Yearly Quantity” means the minimum amount of the Device PURCHASER must procure from the SELLER per year as defined in Exhibit C.

  

	 	1.19	“Purchase Price” shall have the meaning set forth in Exhibit C. 

 

	 	1.20	“Regulatory Authority” or “Regulatory Authorities” means the United States Food and Drug Administration and any divisions thereof, any
equivalent agency of any other country and any division thereof, and any other applicable regulatory body. 

  

					
		  	2	  	***Confidential Treatment Requested

	 	1.21	“Success Fee” means the fee to be paid by PURCHASER to SELLER as specified in Exhibit D upon successful FDA Approval. 

 

	2.	MANUFACTURE AND SALE 

  

	 	2.1	Supply and Purchase Obligations. SELLER agrees to manufacture and sell to PURCHASER, and PURCHASER agrees to purchase from SELLER, such quantities of the Device
as PURCHASER may order from SELLER in accordance with the terms and conditions of this Agreement. 

  

	 	2.2	Device Equipment. Seller will utilize Device Equipment for the manufacture of the Device. Ownership of Device Equipment shall remain with SELLER. In case
PURCHASER wants to obtain ownership of Device Equipment, it shall purchase from SELLER Device Equipment at a price to be agreed between Parties and pay the applicable German VAT at the time of transfer of ownership. No such purchase shall occur
without SELLER’s prior written consent. In no case shall Device Equipment leave SELLER’s premises. 

  

	 	2.3	cGMP Compliance. SELLER shall assemble and package the Device in accordance with the Device Specifications and applicable cGMP as of the Effective Date.

  

	 	2.4	Intellectual Property. Any Intellectual Property owned or controlled as of the Effective Date by PURCHASER, SELLER, or their Affiliates shall remain the absolute
unencumbered property of SELLER and PURCHASER respectively. SELLER shall own all arising Intellectual Property rights related to the Device. SELLER reserves the right to prosecute, maintain and defend SELLER’s Intellectual Property, at
SELLER’s discretion and expense. SELLER’s IP is broadly drafted and includes trade secrets and patents related to the Device. SELLER may have strategic reasons to defend or not such IP and will need flexibility to exercise in its own
discretion, particularly any IP that has applications to other SELLER’s products. 

  

	3.	[...***...] 

  

					
		  	3	  	***Confidential Treatment Requested

	4.	RIGHT OF FIRST REFUSAL 

  

	 	4.1	Grant of Right of First Refusal. PURCHASER hereby grants SELLER the exclusive option (but not the obligation) to supply to PURCHASER all of its requirements of a
Drug Delivery System (as defined below) for any Alternate Route of Administration (as defined below) in accordance with the terms of this Article 4. For the avoidance of doubt, PURCHASER may not purchase from a Third Party, or develop and
manufacture internally, a Drug Delivery System for any Alternate Route of Administration, unless (a) SELLER does not exercise its right of first refusal in accordance with Section 4.4 or (b) the feasibility study referred to in
Section 4.5 below is not successful unless (c) PURCHASER is engaged in active development of such Drug Delivery System prior to the Effective Date. 

 

	 	4.2	Alternate Route of Administration Drug Development. PURCHASER agrees to notify SELLER in accordance with Section 4.4 about all Development Activities of any
“Alternate Route of Administration” for a new drug that occur after the Effective Date. “Alternate Route of Administration” means any route of administration for a drug including, but not limited to the current sublingual
route of administration, intranasal, pulmonary, buccal, topical, ophthalmic, and otic drug delivery but excluding oral solid dosing. 

  

	 	4.3	Alternate Route of Administration Drug Delivery Systems. PURCHASER agrees to notify SELLER about all Development Activities that would utilize any “Drug
Delivery System” for any Alternate Route of Administration. “Drug Delivery Systems” used for Alternate Route of Administration includes but are not limited to all forms of spray devices, metered pumps, metered valves,
continuous valves, dry powder inhalers, unit and bi dose devices, and dispensing closures. 

  

	 	4.4	 Exercise of Right of First Refusal. PURCHASER shall deliver a written notice informing the SELLER of any Development Activities for a new drug
involving an Alternate Route of Administration within [...***...] of starting any such activities, which notice shall include information describing such Development Activities and specify whether any Drug Delivery System is preferred or is
then being researched or assessed. Within [...***...] following SELLER’s receipt of such notice, SELLER shall notify PURCHASER of its intention to exercise the right of first refusal set forth in Section 4.1. If SELLER decides to
exercise such right, then (a) PURCHASER shall provide to SELLER all information related to the applicable Development Activities relevant for the design or manufacture of the Drug Delivery System and (b) SELLER shall have [...***...]
from the date all necessary information and materials are provided by PURCHASER to present a Drug Delivery 

  

					
		  	4	  	***Confidential Treatment Requested

 
System for such Alternate Route of Administration to the PURCHASER, but in no event later than [...***...] from the date of SELLER’s notice unless PURCHASER is responsible for any
delays. 
  

	 	4.5	Feasibility Studies. If SELLER provides to PURCHASER within the allotted time a Drug Delivery System for use with any such Alternate Route of Administration
Development Activities, PURCHASER shall perform a feasibility study with SELLER’s Drug Delivery System in accordance with the terms of a feasibility agreement to be negotiated by the Parties in good faith. If such feasibility study is
successful (as defined in the feasibility agreement), PURCHASER will be required to move forward with SELLER’s Drug Delivery System and the Parties shall then negotiate a supply agreement under terms similar to this Agreement. If the
feasibility study is unsuccessful, PURCHASER is free to seek alternate partners for such Drug Delivery System. 

  

	5.	FORECASTS, ORDERS AND DELIVERY 

  

	 	5.1	Estimates and Forecasts. Prior to FDA Approval and upon SELLER’s request, beginning on the first day of each calendar quarter, PURCHASER shall provide
SELLER a non-binding written rolling estimate of purchases of the Device for the [...***...] following the calendar quarter in which such estimate is submitted (the “Estimate”). The Estimate shall specify the desired delivery
dates for each month submitted. PURCHASER shall use its best efforts to assure that each Estimate is accurate, provided however, that the Parties agree that such Estimate shall not constitute an obligation of PURCHASER to purchase the estimated
quantities contained in the Estimate. 

 Following FDA Approval, on the first day of each calendar quarter,
PURCHASER shall provide SELLER a written rolling forecast of purchases of the Device for the [...***...] following the calendar quarter in which such forecast is submitted (the “Forecast”). The Forecast shall specify the
desired delivery dates for each month submitted. PURCHASER shall use its best efforts to assure that each Forecast is accurate, provided however, that the Parties agree that such Forecast (other than the quantities set forth in the Purchase Order)
shall not constitute an obligation of PURCHASER to purchase the estimated quantities contained in the Forecast and that SELLER may charge PURCHASER for otherwise un-reimbursed charges incurred due to reasonable commitments made by SELLER to
suppliers based on such Forecast. PURCHASER agrees that the first [...***...] of each Forecast shall be a firm purchase order of the Device by PURCHASER for which SELLER is authorized to commence production, and which PURCHASER shall purchase
(the “Purchase Order”). 
  

	 	5.2	 Delivery. SELLER shall manufacture, package and deliver ordered quantities of the Device as long as such orders are within the scope of
confirmed Purchase Orders. SELLER shall promptly notify PURCHASER if it will be unable to deliver any part of an order exceeding the quantities set forth on the confirmation of the Purchase Order. SELLER shall not be obligated to supply in any month
any quantity of the 

  

					
		  	5	  	***Confidential Treatment Requested

	 	 
Device exceeding [...***...] of the Purchase Order, and PURCHASER shall purchase at least [...***...] of the quantities set forth in the Purchase Order. SELLER will use its reasonable
commercial efforts to deliver the Device within the time schedule set forth in the confirmation of the Purchase Order. 

  

	 	5.3	Terms of Delivery. Unless otherwise specified in the Purchase Order, SELLER of the Device to PURCHASER shall be via truck, and shall be delivered EXW Congers, NY
manufacturing site (INCOTERMS 2010) to the place of destination in the United States of America named in the Purchase Order. In the event PURCHASER requests SELLER to transport the Device to PURCHASER via air, PURCHASER shall bear all additional
costs of such air transportation. SELLER shall arrange for transportation of the Device by insured common carrier, or SELLER’s truck to PURCHASER’s specified plant or other designated destination in the United States of America. In the
event PURCHASER requires delivery to destination outside the United States of America, new delivery terms shall be negotiated. The Purchase Price for the Device is based on EXW Congers, NY manufacturing site (INCOTERMS 2010). If the Device is
manufactured outside the United States, SELLER and PURCHASER shall negotiate in good faith to agree on appropriate terms. 

  

	 	5.4	Shipment. SELLER shall ship the Device in multiples of full production lots, as defined in Exhibit C. SELLER shall deliver with each lot a Certificate of
Analysis substantially in the form attached hereto as Exhibit B. 

  

	6.	PRICES AND PAYMENT 

  

	 	6.1	Purchase Price. The Purchase Price for the Device is set forth in Exhibit C. 

 

	 	6.2	Payment for the Device. Payment related to the Device shall be made in full within [...***...] of the date of SELLER’s invoice. SELLER shall date and
send invoices for the Device upon shipment of the Device. 

  

	 	6.3	Taxes. The Purchase Price for the Device does not include any property, license, privilege, sales, service, use, excise, value added, gross receipts, or other
like taxes. PURCHASER agrees to pay or reimburse SELLER for any such taxes that SELLER is required to pay or collect or that are required to be withheld. 

  

	 	6.4	[...***...]. 

  

	 	6.5	Device Equipment Contribution. PURCHASER shall pay the Device Equipment Contribution within [...***...] of the date of the SELLER’s invoice. SELLER
shall date and send invoices upon the milestones defined in Exhibit C. 

  

	 	6.6	Currency. All payments hereunder shall be made in United States Dollars (USD). 

  

					
		  	6	  	***Confidential Treatment Requested

	 	6.7	Interest. If PURCHASER fails to pay the full invoiced amount for the Device, or any part thereof, within [...***...] after the due date, SELLER shall be
entitled (without prejudice to any other right or remedy it may have whether under the terms of this Agreement or otherwise) to charge, in addition to any monies due hereunder, interest on the outstanding amount at the rate of [...***...] or
the highest applicable rate allowed by law, whichever is less, calculated on a daily basis from such date until the date actual payment is made 

  

	 	6.8	Price Revision Due to Changes in Device Specifications. 

  

	 	6.8.1	By PURCHASER. 

 PURCHASER may
request a change, in writing, to the Device Specifications, the manufacturing procedures or control procedures. SELLER will use commercially reasonable efforts to implement the change subject to pricing adjustments, which will be negotiated in good
faith by SELLER and PURCHASER. 
  

	 	6.8.2	By SELLER. 

 SELLER will notify
PURCHASER in writing prior to implementing any change affecting the chemical, biological or physical aspects of the Device. SELLER will not make any changes to the Device Specifications without PURCHASER’s prior written consent shall not be
unreasonably withheld or delayed. SELLER will implement the change subject to pricing adjustments, which will be negotiated in good faith by SELLER and PURCHASER. 
  

	 	6.8.3	By Regulatory Authorities. 

 In
the event of changes required by cGMP’s or other applicable laws or regulations, or in the requirements for the Device, whether written or un-written, by the Regulatory Authorities, SELLER shall have the right to adjust the Purchase Price, such
adjustment being negotiated in good faith by SELLER and PURCHASER. 
  

	7.	REGULATORY RESPONSIBILITY 

  

	 	7.1	Regulatory Responsibility. SELLER shall be responsible, at its sole expense, for complying with applicable regulatory requirements relating to the manufacture of
the Device as applicable in SELLER’ s facilities where the Device is manufactured and, shall use commercially reasonable efforts to perform all of its responsibilities and obligations, including applicable design, development, manufacture,
testing, quality control and documentation activities relating to the Device under or contemplated by this Agreement substantially in accordance with all relevant quality standards that must be met to secure regulatory approval worldwide.

 PURCHASER shall be responsible, at its sole expense, for complying with all other applicable regulatory
requirements relating to the use and sale or resale of the Finished Product. 

  

					
		  	7	  	***Confidential Treatment Requested

	 	7.2	Import and Export Laws. PURCHASER shall comply, at its sole expense, with all export and import regulations and laws necessary to export and import components of
the Device to and from PURCHASER’s premises, including without limitation, procuring and maintaining all import and export licenses necessary to ship from the point of manufacture to PURCHASER’ s premises in accordance herewith and the
payment of all duties, tariffs, surcharges and other customs and other governmental fees levied in connection with the exportation and importation of components of the Device from SELLER to PURCHASER’s premises, or such other location as
designated by PURCHASER. 

  

	8.	QUALITY CONTROL REQUIREMENTS 

  

	 	8.1	Quality 

  

	 	8.1.1	The Parties shall agree upon reasonable release tests to be performed by SELLER prior to shipment of the Device in accordance with applicable regulatory requirements
and subject to pricing conditions. Results of such testing will be supplied in the Certificate of Analysis with each shipment as seen in Exhibit B. 

  

	 	8.1.2	PURCHASER shall send prior written notice of any change requested to be made to Drug Product being delivered by the Device that PURCHASER suspects may affect the Device
Specifications. 

  

	 	8.1.3	Notwithstanding any provision to the contrary in this Agreement, SELLER shall not assign or otherwise delegate any of its obligations to ensure the Device’s
quality or compliance with Device Specifications to any third party other than an Affiliate without consent from the PURCHASER. 

  

	 	8.2	PURCHASER’s Inspections. 

  

	 	8.2.1	The Device shall be subjected to a quality control inspection by PURCHASER in accordance with the Device Specifications set forth in Exhibit A, within
[...***...] as from delivery of the Device to the location designated by PURCHASER in the applicable Purchase Order. 

  

	 	8.2.2	Upon reasonable prior notice, SELLER shall permit PURCHASER to review SELLER’ s quality control procedures and records related to the Device for the purpose of
assuring satisfactory compliance with the Device Specifications and compliance with the provisions of the Quality Agreement. That review shall be conducted in a reasonable manner, during SELLER’s business hours, in the presence of a SELLER
representative and at PURCHASER’s own expense. 

  

	 	8.2.3	 Upon reasonable prior notice, SELLER may permit PURCHASER’s quality assurance personnel to visit SELLER’s production facility, to the extent
that such visit is reasonably required to assure compliance with regulatory requirements or to the extent a review of records alone is not adequate to 

  

					
		  	8	  	***Confidential Treatment Requested

	 	 
assure satisfaction with such quality control requirements. Such visit shall be conducted in a reasonable manner, during SELLER’s business hours, in the presence of a SELLER representative,
at PURCHASER’s own expense and shall be limited to the equipment, records or production actually used in the manufacture of the Device. 

  

	 	8.2.4	SELLER shall (i) participate and cooperate with PURCHASER’s personnel who may visit SELLER’s production facility as provided in this Section 8,
(ii) take corrective action in a timely manner as may be reasonably required by PURCHASER to comply with the provisions of this Agreement and with cGMP requirements when applicable, subject to pricing conditions in Sections 4 and Exhibit
C, and (iii) when requested by PURCHASER, describe in writing, any appropriate corrective action planned or taken. 

  

	 	8.3	Regulatory Inspections. 

  

	 	8.3.1	In the event that any of SELLER’s products, facilities and/or processes that are used for the manufacture of the Device are the subject of an inspection related to
PURCHASER by any Regulatory Authority or any other duly authorized agency of any national, state, or local government, SELLER shall promptly notify PURCHASER of such inspection and shall supply PURCHASER with copies of any correspondence or portions
of correspondence that relate to the Device, as well as SELLER’ s proposed response, if any. 

  

	 	8.3.2	In the event that any of PURCHASER’s facilities that are used for the storage of the Device or the manufacturing of the Finished Product are the subject of an
inspection by any Regulatory Authority or any other duly authorized agency of any national, state, or local government, PURCHASER shall promptly notify SELLER of such inspection and shall supply SELLER with copies of any correspondence or portions
of correspondence that relate to the Device, as well as PURCHASER’s proposed response, if any. 

  

	 	8.3.3	In the event that either Party receives any written communications from any Regulatory Authority in connection with the manufacture, use, or sale of the Device for
PURCHASER, it shall provide the other Party with a copy of each such communication and the proposed response, if any. 

  

	 	8.3.4	Records. SELLER shall retain samples of the Device, batch and other manufacturing and analytical records, records of shipments of the Device and validation data
relating to the Device for a minimum of [...***...] and shall make such data available to PURCHASER and Regulatory Authorities upon PURCHASER’s reasonable request or if required by law. 

 

	9.	REJECTION 

  

	 	9.1	 General. In the event that any portion of the Device delivered to PURCHASER by SELLER shall fail to conform with the Device Specifications,
PURCHASER may 

  

					
		  	9	  	***Confidential Treatment Requested

	 	 
reject that portion by giving written notice within [...***...] following receipt of Products and sending, at SELLER’s expense, the defective samples to SELLER after SELLER’s
acceptance of rejection. Failure to report claim within that period, PURCHASER shall be considered as having accepted delivery and SELLER shall not be held liable with respect to the defective Device. 

 

	 	9.2	Unattributed Defects. In case the Device does not comply with the Device Specifications due to hidden or latent defects that were not noticeable at the time of
inspection by PURCHASER pursuant to Section 8.2, PURCHASER shall immediately inform SELLER of its claims in this respect, at the latest within the later period of [...***...] following the discovery of the defect or any third party or
regulatory claim or liability arising from the defect. Failing any claims within [...***...] in this respect, it shall not be possible to engage SELLER’s liability. Notwithstanding the foregoing, SELLER shall not be liable for any defect
appearing more than [...***...] after the Device (stored and handled in accordance with commercially reasonable standards) is received at PURCHASER’s premises. 

 

	 	9.3	Claims. Any and all claims shall be substantiated and explained in reasonable detail as to the nature of the defects or failure of the Device to comply with the
Device Specifications. PURCHASER shall reasonably provide SELLER with any and all substantiation regarding the reality of the anomalies recorded, notably with defective samples and shall ensure that SELLER has reasonable means of confirming the
existence of such anomalies. 

  

	 	9.4	Rejected Device. If PURCHASER rejects the Device in accordance with this Section 9, and after SELLER’s formal acceptance of such rejection, then, at
SELLER’s expense and discretion, PURCHASER shall return to SELLER any such shipment, or any part thereof, that does not comply with the Device Specifications, and receive in exchange therefore at the option of PURCHASER or SELLER, either
(i) a complete refund of the Purchase Price, taxes paid and not recoverable, and shipping costs associated with the Device in form of a credit note, or (ii) fully compliant replacement Device. If the Parties so agree, PURCHASER shall
destroy any non-conforming Device, at SELLER’s expense and in accordance with all applicable legal requirements. While SELLER is investigating the rejection, payments of purchased goods subject to such rejection shall be put on hold until claim
response is given. 

  

	 	9.5	Disputes. If SELLER disputes PURCHASER’s rejection, the Parties shall submit samples of the rejected Device to a mutually acceptable independent laboratory
for analysis, whose decision in the matter shall be final and binding. The costs of such analysis shall be borne by SELLER unless such analysis shows that the Device conforms to the Device Specifications, in which case PURCHASER shall bear the cost
of such analysis. 

  

	10.	WARRANTY 

  

	 	10.1	SELLER’s Warranty. 

  

					
		  	10	  	***Confidential Treatment Requested

	 	10.1.1	SELLER warrants to PURCHASER that the Device, at the time of delivery to PURCHASER as provided in Section 5.2, will conform in all respects to the Device
Specifications. 

  

	 	10.1.2	SELLER does not warrant that the Device may be suitable for the manufacture of any intermediate or finished product (including the Finished Product).

  

	 	10.1.3	It is the exclusive responsibility of PURCHASER to ensure that (i) the Device shipped from SELLER according to the Device Specifications is adapted to the use
which it is intended for, (ii) that the Device Specifications are adapted to the storage of the Device, (iii) that the Device is compatible with the Drug Product, and (iv) that the Drug Product and the Finished Product (other than the
Device) comply with all applicable laws. 

  

	 	10.1.4	SELLER may, but is not required to, perform tests for compatibility between the Device and the Drug Product. SELLER MAKES NO REPRESENTATION OR WARRANTY THAT ANY TESTS
PERFORMED BY OR ON BEHALF OF SELLER ARE ADEQUATE OR SUFFICIENT FOR PURCHASER’S PURPOSES. PURCHASER AGREES NOT TO HOLD SELLER RESPONSIBLE FOR THE ADEQUACY OR SUFFICIENCY OF SUCH TESTS, OR THE RESULTS DERIVED FROM SUCH TESTS.

  

	 	10.2	Exclusions. The warranty provided under Section 10.1(a) shall not apply to any Device that (i) has been tampered with or otherwise altered by
PURCHASER, its Affiliates or their customers, distributors agents; (ii) has been subjected to misuse, negligence, malice or accident by PURCHASER, its Affiliates or their customers, distributors agents; or (iii) has been stored, handled or
used by PURCHASER, its Affiliates or their customers, distributors agents in a manner contrary to the Device Specifications and the Device Specifications or SELLER’s written instructions which can, among others, define maximum periods for the
use of the Device. 

  

	 	10.3	Limitations on Warranty. THE FOREGOING WARRANTIES ARE EXCLUSIVE AND IN LIEU OF ALL OTHER WARRANTIES OF QUALITY AND PERFORMANCE, WRITTEN, ORAL OR IMPLIED, AND ALL
OTHER WARRANTIES, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT, ARE HEREBY DISCLAIMED BY SELLER. 

 

	 	10.4	LIMITATION OF LIABILITY 

  

	 	10.4.1	 No Consequential Damages. IN NO EVENT SHALL SELLER BE LIABLE FOR SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, whether in warranty,
contract, negligence, tort, strict liability, or otherwise including, but not limited to, loss of profits or revenue, delays, or 

  

					
		  	11	  	***Confidential Treatment Requested

	 	 
claims of customers of PURCHASER or its Affiliates or other third parties for such or other damages. This limitation of liability shall not apply to claims of liability for death or personal
injury caused by SELLER’s gross negligence, willful act, or omission. 

  

	 	10.4.2	Limitation of Liability. Each Party’s cumulative liability to the other Party for all claims relating to the Device and this Agreement, including any cause
of action based on any theory of contract, tort, or strict liability, shall not exceed [...***...]. This limitation of liability shall not apply to claims of liability for death or personal injury caused by either Party’s gross
negligence, willful act, or omission. In this respect, PURCHASER expressly undertakes to inform all of its customers, Affiliates or other third parties of the conditions and maximum periods defined for the use of the Device, by any appropriate means
making it possible to inform the said customers, Affiliates or other third parties, prior to use of the Device. 

  

	11.	INDEMNIFICATION 

  

	 	11.1	SELLER. Subject to the liability limitations set forth in clause 10.4, SELLER shall defend, indemnify and hold PURCHASER and its Affiliates, and their
shareholders, directors, officers, employees and agents harmless from and against any and all liability, loss, damage, recalls, causes of action, suits, claims, demands, settlements, costs and expenses or judgments arising from injury or death to
persons or damage to property, of any nature whatsoever, resulting from the failure of the Device to conform to the warranty set forth under Section 10.1, provided that PURCHASER shall have given prompt notice in writing to SELLER of any such
claim. 

  

	 	11.2	PURCHASER. PURCHASER shall defend, indemnify and hold SELLER and its Affiliates, their shareholders, directors, officers, employees and agents harmless from and
against any and all liability, loss, damage, expense, causes of action, suits, claims, demands, settlements, costs and expenses or judgments of any nature whatsoever, resulting from the Finished Product or its marketing, sale, clinical testing,
clinical use or other use or misuse, including any defect, failure to warn or other Device liability claims, except to the extent SELLER is required to indemnify PURCHASER under Section 10.1 of this Agreement, provided that SELLER shall have
given prompt notice in writing to PURCHASER of any such claim. 

  

	 	11.3	Insurance. Each of SELLER and PURCHASER will use its best efforts, by itself or through its Affiliates’ group insurance policies and at its sole cost and
expense, to procure and maintain adequate General & Products Liability Insurance. In addition, SELLER will use its best efforts, by itself or through its Affiliates’ group insurance policies and at its sole cost and expense, to procure
and maintain adequate Property All Risks Insurance in order to cover the value of the Device Equipment and any components thereof in SELLER’s possession or for which SELLER bears the risk of loss. 

 

	12.	REPRESENTATIONS 

  

					
		  	12	  	***Confidential Treatment Requested

	 	12.1	Each Party hereby represents and warrants that it has the full power and authority to enter into and perform this Agreement, and each Party knows of no contract,
agreement, promise, undertaking or other fact or circumstance that would prevent the full execution and performance of this Agreement. 

  

	13.	TERM AND TERMINATION 

  

	 	13.1	Term. This Agreement shall, unless otherwise terminated, remain in full force and effect for a period of five (5) years from the Effective Date (the
“Initial Term”), at which time, the Parties shall discuss in good faith negotiations an extension of this Agreement. 

  

	 	13.2	Early Termination. Without prejudice to any other rights it may have hereunder or at law or in equity, either Party may terminate this Agreement:

  

	 	13.2.1	immediately if the other Party makes an assignment for the benefit of its creditors or a receiver or custodian is appointed for it or its business is placed under
attachment, garnishment or other process involving a significant portion of its business; 

  

	 	13.2.2	after [...***...] written notice from the terminating Party specifying an alleged material breach (including payment breach) and stating its intent to so
terminate, if the other Party fails to commence and diligently pursue to remedy any such material breach of this Agreement; 

  

	 	13.2.3	immediately if the other Party becomes insolvent, an order for relief is entered against the other Party under any bankruptcy or insolvency laws or laws of similar
import; or 

  

	 	13.2.4	upon [...***...] written notice from the terminating Party if the Device does not receive FDA Approval by January 1, 2013. 

 

	 	13.3	Effect of Termination. Neither termination nor non-renewal of this Agreement shall release either Party from fulfilling any obligations it may have incurred
prior to any such termination, nor prejudice any other rights or remedies that either Party may have at law or in equity. 

 In case of early termination by PURCHASER not due to a breach by SELLER, PURCHASER will compensate SELLER for any costs directly related to the value of the goods or components already incurred by SELLER
on the basis of the Purchase Orders received from PURCHASER according to Section 5.1 above. PURCHASER will also compensate SELLER for any costs associated with stock at SELLER’s or at SELLER’s sub suppliers, including, but not limited
to, rubber stoppers, glass vials, and steel needles; provided SELLER and SELLER’s sub suppliers shall be obligated to take all commercially reasonable measures to mitigate the damages resulting from such remaining inventory. 

  

					
		  	13	  	***Confidential Treatment Requested

	 	13.4	Surviving Clauses. Notwithstanding any such termination, any provision set forth in this Agreement remaining to be performed in whole or in part, capable of
taking effect following termination, or which by its nature is contemplated to survive the termination of this Agreement shall survive and continue in full force and effect despite termination. 

 

	14.	MISCELLANEOUS 

  

	 	14.1	Notices. All notices, requests, demands, waivers, consents, approvals or other communications to any Party hereunder shall be in writing and shall be deemed to
have been duly given if delivered personally to such Party or sent to such Party by facsimile transmission, overnight courier or by registered or certified mail, postage prepaid, to the addresses set forth below (or to such other address as the
addressee may have specified in notice duly given to the sender as provided herein): 

 If to SELLER:

 AptarGroup, Inc. 
 475 West Terra Cotta, Suite E 
 Crystal Lake, IL 60014-9695 USA 

Attn: Chief Operating Officer 
 Phone No.: (815) 477 -0424 
 Fax No.: (815) 477-0481 

With cc to: 

Aptar Congers, a division of AptarGroup, Inc. 
 250 North Route 303 
 Congers, NJ 10920-1408 USA 

Attn: President, Aptar Pharma North America 
 Phone No.: (845) 639-3700 
 Fax No: (845) 639-3900 

If to PURCHASER: 
 Name: INSYS 
 10220 South 51st Street, Suite 2 

Pheonix, AZ 85044 USA 
 Attn: President 
 Phone No.: (602) 910 2617 x9021 

Fax No.: (602) 910-2627 
 Such notice, request, demand, waiver, consent, approval or other communications will be deemed to have been given as of the date so delivered, sent by facsimile transmission with receipt confirmed, or
[...***...] after so mailed. 
  

	 	14.2	Choice of Law. This Agreement, along with the Schedules and Exhibits attached, incorporated and referenced herein and all Purchase Orders issued hereunder shall
be governed and interpreted, and all rights and obligations of the Parties shall be determined, in accordance to the laws of the State of New York. 

  

					
		  	14	  	***Confidential Treatment Requested

	 	14.3	Force Majeure. Neither Party shall be responsible or liable in any way for failure or delay in carrying out the terms of this Agreement resulting from any cause
or circumstance beyond that Party’s reasonable control, including, but not limited to, fire, flood, other natural disasters, war, labor difficulties, interruption of transit, accident, explosion, civil commotion, and acts of any governmental
authority; nor shall SELLER be responsible or liable in any way for failure or delay in carrying out the terms of this Agreement if due to any shortage or inability to obtain any raw materials (including energy), equipment or transportation;
provided, in each case, that the affected Party shall give prompt notice thereof to the other Party. No such failure or delay shall terminate this Agreement, and each Party shall complete its obligations hereunder as promptly as reasonably
practicable following cessation of the cause or circumstances of such failure or delay; provided, that if any of the above conditions continues to exist for more than [...***...] after the date of any notice given with regard thereto, either
Party may terminate this Agreement forthwith upon notice to the other. 

  

	 	14.4	Severability. In the event that any provision of this Agreement shall be found in any jurisdiction to be in violation of public policy or illegal or
unenforceable at law or in equity, such finding shall in no event invalidate any other provision of this Agreement in that jurisdiction, and this Agreement shall be deemed amended to the minimum extent required to comply with the law of such
jurisdiction, such provision being adjusted rather than voided if possible. 

  

	 	14.5	Entire Agreement. This Agreement, including any Schedules and Exhibits attached, incorporated or referenced herein, the Quality Agreement, and the
confidentiality agreement referenced in Section 14.9 set forth the entire agreement reached between the Parties with respect to the transactions contemplated hereby. This Agreement (including all Schedules and Exhibits) may not be amended or
modified except by written instrument duly executed by the Parties hereto stating that it is an amendment to this Agreement. 

 With the reservation of the specific provisions of this Agreement and of the Quality Agreement, SELLER’ s general conditions of sales, attached as Exhibit E, shall apply to all sales closed in the
framework of this Agreement, to the exclusion of any and all general conditions of purchase which may be communicated by PURCHASER. 
 The terms of this Agreement shall take precedence over the Quality Agreement, the confidentiality agreement referenced in Section 14.9 or the standard terms and conditions set forth in Exhibit E if
there is any conflict between them. 
  

	 	14.6	No Waiver. The failure of either Party hereto to enforce at any time, or for any period of time, any provision of this Agreement shall not be construed as a
waiver of such provision or of the right of such Party thereafter to enforce each and every provision. Any waiver by a Party of any of its rights under this Agreement in one or more instances shall be in a writing signed by such Party and shall not
be construed as constituting a continuing waiver or as a waiver in other instances. 

  

					
		  	15	  	***Confidential Treatment Requested

	 	14.7	Assignment, Binding Effect. Neither Party shall assign this Agreement nor any of its respective rights or obligations hereunder without the prior written consent
of the other Party, which consent will not be unreasonably withheld, except to any Affiliate of the assigning Party or by operation of law or as otherwise permitted hereunder. Any such attempted assignment without such consent shall be void. This
Agreement and the rights herein granted shall be binding upon and shall inure to the benefit of PURCHASER and SELLER and their respective successors and permitted assigns. 

 

	 	14.8	Arbitration. Any dispute, controversy or claim arising out of or in connection with this Agreement, or the breach, termination or invalidity hereof, that the
Parties are unable to resolve between themselves, shall be settled by arbitration in accordance with the Rules of Arbitration of the International Chamber of Commerce, and judgment upon the award rendered by the arbitrator(s) may be entered in any
court having jurisdiction thereof. Such proceedings shall take place in New York, USA, and shall be conducted in English. The decision of the arbitration proceeding shall be final and binding upon the Parties. This clause shall not be construed to
limit the right of either Party to apply to any court of competent jurisdiction for injunctive relief for unauthorized use of confidential information. 

  

	 	14.9	Confidentiality. A separate agreement signed April 16, 2010 relating to confidentiality has been entered into by the Parties and that agreement constitutes
the entire agreement and understanding of the Parties relating to the subject matter of confidentiality and supersedes any previous agreement or understanding between the Parties in relation to such subject matter. 

[Signature page follows]. 

  

					
		  	16	  	

 IN WITNESS WHEREOF, this Agreement has been duly executed and delivered as of the day and year first above
written. 

									
		 		 	
					
		 	/s/ Stephen J. Hagge	 		 		 	/s/ Michael Babich
		 	 APTARGROUP, INC.
 Name: Stephen
J. Hagge
 Title: Exec. V.P. & Chief Operating Officer
	 		 		 	 INSYS THERAPEUTICS, INC.

Name: Michael Babich
 Title: President and
CEO

 [Signature page of Supply Agreement between AptarGroup, Inc. and Insys Therapeutics, Inc.]

  
 17 

 EXHIBIT A: DEVICE SPECIFICATION 

[...***...] 

  

					
		  	18	  	***Confidential Treatment Requested

 EXHIBIT B: SELLER CERTIFICATE OF ANALYSIS + SELLER STANDARD 

SPECIFICATION 
 [...***...] 

  

					
		  	19	  	***Confidential Treatment Requested

 EXHIBIT C: PURCHASE PRICE 
 The purchase price for the Device (“Purchase Price”) is based on the procured annual quantities of the Device in accordance with Table C1 below: 

Table C.1 Device Purchasing Price Levels 
  

					
	 Price Level
	  	 Quantities (pieces)
	  	 Price ([...***...])

	 1
	  	[...***...]	  	$[...***...]
	 2
	  	[...***...]	  	$[...***...]
	 3
	  	[...***...]	  	$[...***...]
	 4
	  	[...***...]	  	$[...***...]
	 5
	  	[...***...]	  	$[...***...]

 Notwithstanding the above, SELLER grants PURCHASER a Purchase Price equal to Price Level [...***...] subject to
PURCHASER’s procurement of the yearly quantity of units of the Device from the SELLER as described below in Table C.2. Year 1 is defined as the time period leading up to FDA Approval and the first year from the date of FDA Approval of the
Finished Product. For this time period a price of $[...***...] will be offered as long as Year 1 Minimum Yearly Quantity is met. Year 2 is defined as the second year from the date following FDA Approval. For this time period a price of
$[...***...] will be offered as long as Year 2 Minimum Yearly Quantity is met. Year 3 is defined as the third year from the date following FDA Approval of the Finished Product. For this time period a price of $[...***...] will be offered
as long as Year 3 Minimum Yearly Quantity is met. Year 4 is defined as the fourth year from the date following FDA Approval of the Finished Product. For this time period a price of $[...***...] will be offered as long as Year 4 Minimum Yearly
Quantity is met. 
 Table C.2 Minimum Yearly Quantities 
  

							
	 Year
	  	 Minimum Yearly

Quantity
	  	Cumulative Yearly
Quantity	  	Price ([...***...])
				
	 1
	  	[...***...]	  	[...***...]	  	$[...***...]
				
	 2
	  	[...***...]	  	[...***...]	  	$[...***...]
				
	 3
	  	[...***...]	  	[...***...]	  	$[...***...]
				
	 4
	  	[...***...]	  	[...***...]	  	$[...***...]

 In case PURCHASER has not met the Minimum Yearly Quantities set forth in Table C.2 for any reason other than for
SELLER’s fault, pricing for the quantities purchased will be adjusted to the appropriate pricing level as outlined in Table C.1 above and a supplemental invoice will be issued for the difference retroactively at the end of Year 1, Year 2, Year
3 and Year 4 and PURCHASER will pay the resulting difference to SELLER. At the end of the then current Year, SELLER shall calculate the Minimum Yearly Quantities based on the quantities of the Device delivered to PURCHASER pursuant to Purchase
Orders placed for such year. At such time, if PURCHASER has not met the Minimum Yearly Quantities, then SELLER shall send an invoice setting forth (i) a calculation of the actual shipped quantities of the Device at the applicable Purchase Price
and (ii) the difference between such due amount and any amounts paid by 

  

					
		  	20	  	***Confidential Treatment Requested

 
PURCHASER as of such date. PURCHASER shall pay such invoiced amount in full within [...***...] of the date of SELLER’s invoice. 

In the event that Purchaser fails to fulfill the Minimum Yearly Quantities for [...***...] and [...***...], SELLER retains the right to
reevaluate the Price Levels as set forth above in Schedule C.1, taking into account the Producer Price Index (“All Other Plastics Product Manufacturing”) from the US Bureau of Labor Statistics. 

The Parties agree to meet in good faith to discuss extension of supply no later than [...***...] prior to the end of the Year 4 as set forth in
this Agreement. SELLER agrees to extend the supply term in one-year increments, beginning Year 5, provided, SELLER and PURCHASER find an agreement on terms and conditions similar to the ones set forth in this Agreement. In particular prices need to
be agreed by SELLER prior to any extension of this Agreement. Year 5 is defined as the fifth year following FDA Approval of the Finished Product. 
 The Parties agree that prices may be adjusted annually based on the Producer Price Index (“All Other Plastics Product Manufacturing”) from the US Bureau of Labor Statistics. 

The lot size for the Device is no less than [...***...] units and no more than [...***...] units. 

The SELLER’s standard packaging and packing specifications are attached in Exhibit F. 

Currency Adjustments. 
 SELLER shall
calculate the impact of such evolution and inform PURCHASER accordingly. For purposes of clarity, this mechanism is designed for the parties to share the risk of currency fluctuations. 
 Currency adjustments only apply for products related to the Device made and imported from Europe (“Imported Products”). As of the Effective Date, two (2) components of the device are
imported from Europe. 
 [...***...] 
 [...***...] 
 On [...***...] of each year of this Agreement (the
“Currency Adjustment Date”), the Purchase Price of Imported Products only will be revised to reflect fluctuation of the currency exchange rate between the US Dollar and the Euro, compared to the initial base exchange rate on
December 31st, 2009, which shall be [€1
=US$1.40] (the “Base Rate”). On each Currency Adjustment Date, the average exchange rate of the Euro to the US Dollar shall be calculated since the Effective Date or for the prior twelve (12) months. If such floating average
differs from the Base Rate then in effect by at least [...***...] then, and only then, will the percentage change (positive or negative) to the exchange rate over such twelve (12) month period shall be computed and [...***...] of
such percentage change shall be multiplied by the then current US Price to determine the actual US Price that SELLER will invoice to PURCHASER 

  

					
		  	21	  	***Confidential Treatment Requested

 
for all Devices shipped to PURCHASER for after such Currency Adjustment Date. Examples of the calculation of the currency adjustment described herein are set forth below. 

Sample Calculation for Currency Pricing Adjustment 
 1) If the Floating Average Rate as of [...***...] = [...***...], then NO CHANGE ([...***...] è 1.40 < [...***...]). 

2) If the Floating Average Rate as of [...***...] = [...***...], the Price will be adjusted as follows: 

[...***...] 
 Device Equipment
Contribution 
 The Device Equipment Contribution to be paid by PURCHASER to SELLER is US-$ [...***...]. This contribution includes
SELLER’s standard validation process. Any extra work, such as, but not limited to, analytical testing, performance studies or extractable studies, shall be subject to reasonable commercial terms. 

Invoice Milestones for Device Equipment Costs 
  

			
	 First Payment:
	  	US-$[...***...]
	 Milestone: the Effective Date.
	  	
	 Second Payment:
	  	US-$[...***...]
	 Milestone: first available samples of all components out of moulds.
	  	
	 Third payment:
	  	US-$[...***...]
	 Milestone: qualified components within specification.
	  	
	 Fourth payment:
	  	US-$[...***...]
	 Milestone: Operational Qualification, Installation Qualification, Performance Qualification of assembly
equipment.
	  	

 All prices for Device Equipment are calculated using an exchange rate of 1€ = 1.40 US-$. On any day that any
milestone payment for the Device Equipment is invoiced by SELLER to PURCHASER, the US-$ amount shall be calculated utilizing an exchange rate equal to the final daily exchange rate as published in the Wall Street Journal, or if the Wall Street
Journal ceases to publish an exchange rate, such comparable publication. 

  

					
		  	22	  	***Confidential Treatment Requested

 EXHIBIT D: [...***...] 

[...***...] 

  

					
		  	23	  	***Confidential Treatment Requested

 

 

  
 25 

 

 

  
 26 

 EXHIBIT F: STANDARD PACKAGING AND PACKING SPECIFICATIONS 

 

	1.	Packing 

  

	 	1.1.	Bag Preparation 

  

	 	1.1.1.	[...***...] 

	 	1.1.2.	[...***...] 

	 	1.1.3.	[...***...] 

	 	1.1.4.	[...***...] 

  

	 	1.2.	Carton Sealing 

  

	 	1.2.1.	[...***...] 

  

	 	1.3.	Carton filling/ Pharmaceutical Packaging Area 

  

	 	1.3.1.	[...***...] 

	 	1.3.2.	[...***...] 

	 	1.3.3.	[...***...] 

	 	1.3.4.	[...***...] 

	 	1.3.5.	[...***...] 

  

	 	1.4.	Labeling and closing of carton 

  

	 	1.4.1.	[...***...] 

	 	1.4.2.	[...***...] 

	 	1.4.3.	[...***...] 

	 	1.4.4.	[...***...] 

  

	 	1.5.	Packaging Records 

  

	 	1.5.1.	[...***...] 

  

	 	1.6.	Palletization 

  

	 	1.6.1.	[...***...] 

	 	1.6.2.	[...***...] 

  

	 	1.7.	Shipment preparation 

  

	 	1.7.1.	[...***...] 

  

  

					
		  	27	  	***Confidential Treatment Requested

	 	1.7.2.	[...***...] 

	 	1.7.3.	[...***...] 

	 	1.7.4.	[...***...] 

	 	1.7.5.	[...***...] 

	 	1.7.6.	[...***...] 

	 	1.7.7.	[...***...] 

  

	 	1.8.	Stretch Wrap 

  

	 	1.8.1.	[...***...] 

	 	1.8.2.	[...***...] 

	 	1.8.3.	[...***...] 

  

	 	1.9.	Paperwork 

  

	 	1.9.1.	[...***...] 

	 	1.9.2.	[...***...] 

	 	1.9.3.	[...***...] 

  

	 	1.10.	Bill of Lading 

  

	 	1.10.1.	[...***...] 

	 	1.10.2.	[...***...] 

  

	 	1.11.	Pick up by carrier 

  

	 	1.11.1.	[...***...] 

  

  

					
		  	28	  	***Confidential Treatment Requested

	 	1.11.2.	[...***...] 

	 	1.11.3.	[...***...] 

  

	 	1.12.	Communication of Shipment 

  

	 	1.12.1.	[...***...] 

	 	1.12.2.	[...***...] 

	 	1.12.3.	[...***...] 

  

	 	1.13.	Palletization of Finished Products: 

  

	 	1.13.1.	[...***...] 

	 	1.13.2.	[...***...] 

	 	1.13.3.	[...***...] 

	 	1.13.4.	[...***...] 

	 	1.13.5.	[...***...] 

	 	1.13.6.	[...***...] 

	 	1.13.7.	[...***...] 

	 	1.13.8.	[...***...] 

	 	1.13.9.	[...***...] 

  

					
		  	29	  	***Confidential Treatment Requested

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00191-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00191-of-00352.parquet"}]]